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Antibiotics and other antimicrobial agents have been used in swine diets for more 
than 50 years to improve growth performance and overall health status of pigs.  
Significant improvements in growth rate, feed efficiency, and economic gains are 
observed in all phases of growth.  However, a growing concern over the development of 
antibiotic resistance with the use of antimicrobial agents, in particular at subtherapeutic 
levels, has been raised by consumers and medical groups.  Although numerous studies 
have been conducted that prove otherwise, the pressure by such groups could lead to the 
potential banning of antibiotics for growth promotion, which is now being implemented 
in European Union countries.  In the event of a ban, growth performance would likely be 
reduced and the cost of production would be increased.  Thus, there is a need to evaluate 
alternatives that would mimic the positive response of antibiotic growth promotants.  
 The alternatives currently on the market have varying mechanisms that focus on 
gut microflora and immunity of pigs.  Some of these alternatives, such as acidifiers, 
probiotics, mannan oligosaccharides, and beta-glucan, have the potential to substitute for 
antibiotics in swine diets.  However, improvements in swine growth performance due to 
these alternatives usually have been variable and inconsistent.  Thus, there is a need to 
continue to evaluate these alternatives and their combination as a replacement to 






For more than 50 years, antibiotics and other antimicrobial agents have been 
incorporated in animal feeds to improve overall health and growth performance of farm 
animals, in particular swine.  Swine feeds often contain antimicrobial agents with an 
estimated presence of 80% to 90% in starter diets, 70% to 80% in grower diets, 50% to 
60% in finisher diets, and 40% to 50% in sow diets (Cromwell, 2001).  These 
antimicrobial agents are used therapeutically, to treat, control and prevent diseases, and 
subtherapeutically, to improve overall growth rate and efficiency (Cromwell, 2001; Shea, 
2004; Harper, 2004; Mathews, 2001; Mathew and Ebner, 2004).  Moreover, 
subtherapeutic use of antibiotics reduces mortality and morbidity, improves reproductive 
performance, and increases profit (Cromwell, 2001). 
Over 1,000 experiments have been conducted in the United States from 1950 to 
1985 that showed improvements in growth rate and feed efficiency in pigs, in all phases 
of growth, with the use of antibiotics.  The addition of antibiotics in diets increased 
growth rate by 16.4% in young pigs (7 to 25 kg), 10.6% in growing pigs (17 to 49 kg), 
and 4.2% in the growing-finishing stage (24 to 89 kg), and feed efficiency also was 
improved by 6.9%, 4.5% and 2.2%, respectively (Cromwell, 2001).  Using these 
parameters, Cromwell (2002) calculated a net return of $2.99 per pig from weaning to 
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market weight using chlortetracycline as the antibiotic in the diet at a cost of $0.20 per 
pig in starter and $0.50 per pig in grow-finish.  For gestating sows fed with 
chlortetracycline at a cost of $0.49 per litter, a conservative assumption of a 5% 
improvement in farrowing rate and 1/3 pig per litter increase translated to a very 
significant net return of $7.12 per litter.     
 
Concern on antibiotic resistance 
 Despite the significant benefits of antibiotic usage for farm animals, concerns 
related to the development of antibiotic or antimicrobial resistance in animal and human 
medicine have increased in particular with subtherapeutic use of antibiotics.  Of the 45% 
of antibiotics used in all animals in the U.S., 14% are used subtherapeutically; thus, 
approximately 6% of all antibiotics are used for growth promotion (Messenger, 2003; 
Smith, 2002).  A survey by the Animal Health Institute in February 2000 reported that in 
1998, 17.8 million pounds of antimicrobials were used in animal production of which 
14.7 million pounds or 83% were used as therapeutics and only 3.1 million pounds or 
17% were used as growth promotants (McEwen and Fedorka-Cray, 2002).  Smith (2002) 
stated the WHO estimates that 40% of all antibiotics used in human medicine are 
unnecessary where millions of antibiotic prescriptions are written for colds, bronchitis 
and other respiratory infections caused by viruses that do not respond to antibiotics. He 
further added that pound for pound, humans use about 10 times more antibiotics than 
farm animals.  Nevertheless, because the majority of antibiotics being used today in 
animal feeds are the same as that used in human medicine (Mathews, 2001; Shea, 2004; 
Chee-Sanford et al., 2001; Phillips et al., 2004), an overwhelming concern and pressure 
from health specialists and consumer-activist groups (Braude, 1978; Kunin, 1993; 
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Cassell, 1995) to ban the use of antibiotics as growth promotants in farm animals have 
arisen. 
In a more recent report by Florini et al. (2005), they estimated that 70% of the 
antibiotics used in the United States each year are used for growth promotion due to 
overcrowding, stressful, and unsanitary conditions of commercial farms.  Moreover, they 
reported that of the 26.5 million pounds of total antibiotic feed additives used in the 
United States, 42% are accounted for by swine.  However, this percentage goes up to 
69% if the medically important antibiotics, such as penicillins, aminoglycosides, 
macrolides, sulfonamides, tetracyclines, streptogramins, and clindamycin/lincomycin, are 
considered. They also stated in their report that with the use of antibiotic feed additives, it 
resulted in an annual excretion of 13.5 million pounds of antibiotics in animal wastes, of 
which swine account for 47% of all antibiotics feed additives, whereas it is 72% for the 
medically important antibiotics. 
The subtherapeutic use of antibiotics creates selection pressure on the microbial 
population (Shea, 2004), and the chronic exposure of bacteria to low doses of broad-
spectrum antimicrobial agents leads to the development of resistant genes for both 
animals and humans, as evidenced by several studies (Levy et al., 1976; Aarestrup and 
Carstensen, 1998; Mathew and Garner, 2003; Langlois et al., 1983).  As outlined in 
Figure 2.1, the resistant genes from the farm animals could be transferred to humans in 
three pathways; through the food chain by consuming the meat, through contamination 
from the sewage, and through contamination from the animal feeds (Philips et al., 2004).  
However, only a small fraction of harmful bacteria affects both animals and humans with 
even a lesser percentage of resistant bacteria (Mathews, 2001; Figure 2.2).  Furthermore, 
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a long-term study done by Langlois et al. (1986) on the use of tetracycline at 
subtherapeutic levels, resulted in a negligible increase in antibiotic resistance.   
 
Figure 2.1. Some routes of transmission of antibiotic-susceptible or –resistant  
 gastrointestinal or normal intestinal flora between animals and humans 
 (Philips et al., 2004). 
 
Cromwell (2001) also compiled several animal studies from Hays (1977) and 
Zimmerman (1986) on antibiotics that have been used more than 50 years and found that 
there was no significant change in their effectiveness.  A recent antibiotic research 
assessment sponsored by Elanco Animal Health (2003) was performed using a semi-
quantitative mathematical model for two macrolide animal antibiotics (tylosin and 
tilmicosin) on their impact on food safety when used in food animal production.  These 
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researchers found that a person has an overwhelming low risk of acquiring food-borne 
bacteria resistance from eating the meat of animals treated with either of the two 
macrolides.  Eating pork treated with tylosin and tilmicosin has a probability of acquiring 
resistant infection resulting in treatment failure of less than one out of 53 million people 
per year for resistant Campylobacter, and less than one out of 21 billion people per year 
for Enterococcus faecium (Elanco Animal Health, 2003).  
Figure 2.2.  Universe of bacteria (Mathews, 2001). 
 
European Union ban on antibiotics as growth promotants 
 Due to the growing concern of antibiotic resistance transmission from animals to 
humans, several countries already have banned the use of antibiotics and other 
antimicrobial agents as growth promotants.  Sweden started the ban in 1986, followed by 
Denmark in 1995, and based on the Precautionary Principle, where regulatory action was 
implemented to control potentially hazardous substances in the absence of established 
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scientific evidence (Animal Health Institute, 2005), five antibiotic growth promoters have 
been banned in European Union countries since 1997 (Casewell et al., 2003).   
Following the ban, piglet production in Sweden experienced significant clinical 
problems, such as a two-fold increase in post-weaning diarrhea, which resulted in a 75% 
increase in the therapeutic use of antibiotics (Wierup, 2001; Krause and Graham, 2004).  
Stein (2002) further reported a 1.5% increase in mortality, 2 to 3 kg increase in feed 
consumption, and a reduction in daily gain.  But since the ban, there was a decrease in the 
total use of antibacterial drugs administered to animals by 55% and antimicrobial 
resistance has been maintained to relatively low levels of prevalence.   
In Denmark, the use of antibiotic growth promoters decreased by 50% but the 
therapeutic use has not changed (Hayes and Jensen, 2003).  In a review by WHO (2002), 
weanling pigs had an increase in mortality by 0.5% and a 2.6% reduction in weight gain 
when antimicrobial growth promoters were terminated.  Hayes and Jensen (2003) further 
added that the cost of the antibiotic ban in Denmark ranged from $3 to $4.50 per pig. 
 
Effects of a ban in the United States 
 The U.S. food-animal industry is under extreme scrutiny from medical and 
environmental groups, the legislative body, and the corporate and public consumers for 
its use of antimicrobials for growth promotion (Pork News Source, 2005, 2003; 
Messenger, 2002).  Even the World Health Organization in August 2003 recommended a 
worldwide ban on the use of growth-antibiotics in animal feed in spite of the absence of a 
risk-based evaluation (Kaufman, 2003; Messenger, 2004).  Although a single case of 
antibiotic use in food-producing animals causing human antibiotic resistance has yet to be 
proven from over 40 years of research (Avery, 2002), the U.S. FDA (2003) released a 
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document (Guidance for Industry #152) for safety assessment of new antimicrobial drugs 
with regard to their microbiological effects on bacteria of human health concern.  The 
guidance was made in spite of the decline in antibiotic usage in the U.S. from 23.7 
million pounds in 2000 to 21.8 million pounds in 2001 (Pork News Source, 2002).  In 
addition, the Preservation of Antibiotics for Medical Treatment Act of 2005 may 
potentially eliminate novel drug development as new treatments for emerging animal 
diseases (Pork News Source, 2005).  
 In the likelihood of an antibiotic ban for growth promotion, Hayes et al. (2002) 
reported that feed efficiency would be reduced by 1.5%; an increase of 1.5% in the post-
weaning mortality; a decline in yearly sow productivity by 4.82%; and an additional 
$0.25 cost per pig for veterinary and therapeutic drug use.  These most-likely case 
scenarios would increase the cost per head by $6.05 in the first year and by $5.24 per 
head by the end of a 10-year period, which would result in a decline in the net profit per 
head of $4.17 and $0.79 in the first year period and at the end of a 10-year period, 
respectively (Hayes et al., 1999).  It would also increase the retail price of pork by $0.052 
per pound resulting in an extra cost nationally of $748 million per year.  Mathews (2001) 
also predicted a net loss of $45.5 million for the U.S. swine industry as a result of not 
using antimicrobial drugs in swine production.  
 
Alternatives to antibiotics in swine diets 
 As a consequence of the ban on antibiotic usage for growth promotion in the 
European Union countries, swine producers altered management and feeding strategies, 
applying basic biological and physiological principles to improve pig performance and 
reduce economic loss (Stein, 2002).  Some of the alternative feed and management 
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strategies incorporated were: a) increase in nutrient concentration of the diet; b) 
improvement in substrate digestibility and availability; c) modification of gut acidity; d) 
use of probiotic organisms or competitive exclusion technology; e) manipulation of the 
immune system; f) application of antimicrobial property concepts; g) use different 
management and environmental controls; and h) change direction of genetic selection 
(Hardy, 2002).   
 Of the modifications and strategies mentioned above, the alternatives given the 
most consideration were those that focused on the gut microbiota and immunity of the 
pigs, especially at the nursery stage (Krause, 2003; Mathew, 2002).  These alternatives 
included acidifiers, probiotics, mannan oligosaccharides, and immune enhancers, wherein 
their addition to the diet would provide improvements in pig growth performance and 
overall health (Mathew, 2002).  The digestive tract, especially for younger animals, needs 
to have an acidic, low pH environment for proper protein digestion and prohibition of 
bacterial growth (Dinsmore et al., 1997; Hardy, 2003).  Thus, acidifiers, either organic, 
inorganic, or a combination of both may help young pigs overcome post-weaning stress 
and diseases caused by pathogens (Hardy, 2002; Hardy, 2003).   
Probiotics, on the other hand, are live-microbial feed supplements that improve 
intestinal microbial balance of the animal (Kelly, 2004).  However, their results are rather 
inconsistent due to differences in strain of organism used, dosage level, diet composition, 
feeding strategy, feed form and interaction with other dietary feed additives (Chesson, 
1994).  Changes in daily gain ranges from -8.5% to +10.5% and feed efficiency from       
-1.4% to +21.4% (Pollmann, 1992; Hardy, 2002).   
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Another product that is gaining considerable attention as a potential alternative for 
antibiotic growth promotants is mannan oligosaccharides (MOS).  They are made up of 
complex polymers of mannose derived from yeast cell walls (Tizard et al., 1989).  
Mannan oligosaccharides act as a prebiotic that beneficially affects the host by selective 
stimulation of favorable bacteria in the lower gastrointestinal tract, thus improving the 
health of the animal (Gibson and Roberfroid, 1995).  Moreover, MOS bind on specific 
sites of the pathogenic bacteria, allowing the beneficial microorganisms to colonize the 
gut (Cromwell, 2001).  But as with other alternatives, the effects of MOS on animal 
performance are inconsistent.  Supplementation of MOS in three different nursery 
facilities resulted in variable outcomes on growth performances of weanling pigs which 
may be due to differences in sanitation, disease history, and health status of the pigs 
(Rozeboom et al., 2001; Turner et al., 2001). 
For the immune enhancers, a product known as beta-glucan can be used to 
stimulate non-specific defense mechanism in animals (Hardy, 2003).  Present in some 
plants, and yeast cell walls, it activates both innate and adaptive immune responses that 
could decrease the animal’s susceptibility to disease and increase growth performance 
(Blecha and Charley, 1990).  Previous experiments performed with weanling (Dritz, et 
al., 1995; Decuypere et al., 1998; Hiss and Sauerwein, 2003; van Nevel et al., 2003) and 
finishing pigs (Fortin et al., 2003) using different beta-glucan sources, reported variable 
effects on growth and immune parameters.  
 Currently, there is an on-going debate as to the extent of the effect of 
antimicrobials being used at subtherapeutic levels in the development of antibiotic 
resistance in animals and humans.  But with the increasing pressure from consumer 
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groups and the government, the swine industry must be prepared to address a ban on 
antibiotic growth promotants.  Aside from using alternative feed ingredients, non-
nutritional strategies must be employed to compensate for the ban on antibiotic growth 
promotants and maintain the growth and performance of pigs with a product that is 
healthy, safe and acceptable to the consumer.  
 
Gut mechanism and competitive exclusion 
 The gastrointestinal tract functions not only as a site for digestion and absorption 
of nutrients, but it also aids in the immune response of the animal, since it serves as a host 
of intestinal microflora that maintain gut health (Hardy, 2003).  The intestinal epithelium 
of the gastrointestinal tract, with its high cell turnover rate and constant production of a 
protective mucus coat, provides not only an extensive surface area for absorption of 
digested nutrients, but also serves as a barrier to pathogenic bacteria and antigens 
(Gaskins, 2001; Gaskins and Kelly, 1995; Webel et al., 2003).  On the other hand, the 
microbial ecology has an important role in the maintenance of integrity of the enterocyte, 
modulation of metabolic and immunologic processes, and protection against colonization 
by invasive pathogens (Levy, 2000).  This relationship between the intestine and the 
microflora was explained by a study of Hooper et al. (2001), where the commensal 
bacterium influenced the gene expression of the host’s intestine functions (i.e. nutrient 
absorption, mucosal barrier fortification, xenobiotic formation, angiogenesis, and 
postnatal intestinal maturation).  
 Despite the high population density, extensive diversity, and complexity of 
interaction, the microflora that reside in the gastrointestinal tract of an animal can be 
distinctly categorized between indigenous and nonindigenous bacteria (Gaskins, 2001).  
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The indigenous bacteria are those that were present during the animal’s evolution, which 
are ubiquitous in the community, and the true pathogens that have been accidentally 
acquired and are capable of persisting in the gastrointestinal tract, while the 
nonindigenous bacteria are those that are derived from the environment but do not 
colonize the gastrointestinal tract (Dubos et al., 1965; Savage, 1977).  In all of these, a 
balance between beneficial and pathogenic bacteria and their interaction with the 
gastrointestinal tract must be established to maintain the integrity and health of the 
animal (Gaskins, 2001).  
Competitive exclusion, as defined by Gaskins (2001) and Genovese (2003), is an 
applied application of oral supplements of either defined or undefined mixed bacterial 
cultures derived from a normal gut bacterial microflora given to animals to prevent 
intestinal colonization by pathogens that cause food born disease and disease affecting 
the animal.  It has been shown that the competitive exclusion cultures, when administered 
to piglets, were effective against Salmonella and Escherichia coli infections in swine 
with decreased shedding, intestinal colonization, and reduced mortality and morbidity 
(Genovese et al., 2003).  Baum and Harris (2000) also reported a reduction in the number 
of infected pigs that were culture-positive for Salmonella typhimurium and a reduction in 
the duration of S. typhimurium shedding from tonsil and fecal samples when fed with 
Lactobacillus spp. cultures.  
 
Post weaning lag 
 At weaning, piglets experience stress from nutritional, environmental, and social 
changes resulting in post weaning lag, a period of little or no growth (Pieterse, 2000; 
Pluske et al., 1997).  This period is further accompanied with a reduction in feed intake 
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due to the change of the diet from liquid milk provided by the sow to a solid feed that 
leads to scouring or diarrhea of the weanling pig with its limited digestive enzyme 
capacity and immature immune system (van Heugten, 1997; Coffey and Cromwell, 
2001).  The decrease in feed intake reduces the protein mass and DNA content of small 
intestine (Burrin and Stoll, 2003) affecting its integrity.  This, in turn, could compromise 
the pig’s ability to properly digest and absorb nutrients, and also to resist enteric 
pathogens (Webel et al., 2003).  Furthermore, dietary restrictions would also decrease the 
thickness of the mucosa, villous height and width, and villous surface area (Nunez et al., 
1996).  These changes were described by Pluske et al. (1997) as villous atrophy and crypt 
hyperplasia, which are evident at weaning.  
 There are several factors leading to villous atrophy and crypt hyperplasia in 
weanling pigs.  Cera et al. (1988) studied the effect of age and weaning on small 
intestinal growth and morphology of piglets and found that the jejunal villous were 
shorter in weaned pigs compared to that of pigs that remained suckling with the sow.  
Exposure to pathogens after weaning also resulted in a reduction in villous height 
(Vellenga et al., 1992), and net absorption of fluid and electrolytes in the small intestine 
(Nabuurs et al., 1994).  The type of ingredients, especially the protein source, in the diet 
of the young pig also has an effect on the small intestine. For example, soybean meal 
decreased villous height, deformed the villi shape, and increased lamina propria depth as 
a result of less enterocyte maturation on the villi, and the presence of antigenic materials 
and other antinutritional factors (Dunsford et al., 1989; Li et al., 1991).  
 The stress associated with post-weaning lag can be prevented with good 
nutritional management using highly digestible and palatable ingredients, with proper 
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consideration given to nutrient levels and feeding methods, that aim to increase feed 
intake for faster development of digestive enzymes (van Heugten, 1997).  Carbohydrate 
sources containing 20 to 25% lactose, such as dried whey and lactose, and protein 
sources, such as fish meal, skim milk, soy protein concentrate and plasma protein, can be 
used in weanling pig diets, along with other additives like zinc oxide, copper sulfate, 
synthetic amino acids, acidifiers, and other growth-promoting additives (van Heugten, 
1997).  Among these ingredients, the use of spray-dried animal plasma (SDAP) has been 
used more frequently in weanling pig diets.  A review by van Dijk et al. (2001) reported 
that SDAP at 6% in the diet increased the average daily gain, average daily feed intake 
and improves feed efficiency.  A similar extensive review by Coffey and Cromwell 
(2001), using around 7% of SDAP in 79 experiments involving more than 8,000 weaned 
pigs, reported an average improvement in growth rate and feed intake of 25% and 21%, 
respectively, and improvement in feed efficiency by 4%.  
 
Definition and response of antibiotic usage 
 Antimicrobial agents have been used in swine diets to improve overall health, 
growth and performance, and carcass quality.  As defined by Cromwell (2001), 
antimicrobial agents are substances that kill or suppress the growth of bacteria, which 
include antibiotics and chemotherapeutics.  He further defined antibiotics as substances 
produced by living organisms, such as yeast and molds, while chemotherapeutics are 
substances that are chemically synthesized.  These antimicrobial agents are administered 
via injection, feed, and water, and used as therapeutics, prophylactics, and as growth 
promoters (USDA, 1999).  Therapeutic use of antibiotics is administered at dosage levels 
sufficient to treat, control, or prevent clinical disease of bacteria origin, while 
15
prophylactic application is the use of small, subtherapeutic doses that prevent or limit the 
occurrence of bacterial disease, which leads to growth promotion (Animal Health 
Institute, 2005).  
 Along with the improvement in the growth and health of pigs, antibiotics have 
been more cost effective due to the decrease in price to $20 to $40 per kg from a high of 
$200 to $220 per kg (Cromwell, 2001).  With a total feed cost for all U.S. hogs of about 
$5 billion in 1999, a 1.25% improvement in feed efficiency would save the swine 
industry approximately $63 million in feed costs (Mathews, 2001).  In young pigs, the 
use of antibiotics as compared to non-inclusion not only improved daily gain and feed 
conversion ratio by 26% and 10%, respectively, but it also reduced mortality from 4.3% 
to 2.0%, with a more pronounced effect on farms with high-disease level (15.6% to 
3.1%).  These changes translate to a net-return per pig of $1.51 (Cromwell, 2002).  For 
grow-finish pigs, a conservative improvement in daily gain and feed efficiency would 
result in a net return per pig of $1.48 (Cromwell, 2002).  Another report estimated the 
breakeven production cost of using subtherapeutic antibiotics of $44.52/ 100 lb gain 
compared to $42.36/ 100 lb gain in non-usage for a difference of $2.16/ 100 lb gain or 
$5.39 per 250 lb market weight of pig (Holden et al., 2002). 
 
Antibiotic mechanism on growth and development of resistance 
 Antibiotics treat, prevent and maintain overall health of the animal by its action 
with the bacteria either thru 1) interference with cell wall synthesis, 2) interference with 
peptide initiation and/or elongation, 3) interference with DNA replication, or 4) 
interference with the folic acid synthesis pathway (Garold et al., 1973; Plumb, 1995; 
Prescott et al., 2000).  As growth promotants, antibiotics exert their effects by 1) 
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hindering sub-clinical infections, 2) lessening growth-depressing microbial metabolites, 
3) lessening microbial use of nutrients, and 4) increasing uptake and use of nutrients 
(Francois, 1962; Visek, 1978; Anderson et al., 1999; Gaskins et al., 2002).  The disease 
control, metabolic, and nutritional effect of antimicrobial growth promoters affects not 
only the bacteria/pathogens but the animal as well.  The effects of antibiotics in the gut of 
the animal are shown in Figure 2.3. 
Figure 2.3.  Diagram of the proposed effects of antibiotics mediated through their effects  
 on small intestinal microflora (Anderson et al., 1999). 
 
Despite the advantages of using antibiotics for growth promotion, there is a strong 
pressure from consumers and the government to ban the use due to fear of food-
producing animals developing antibiotic resistance that can be transferred to humans.  
Antibiotic resistance, as defined by the Animal Health Institute (2005), is the ability of 
17
microorganisms, such as bacteria, to withstand antibiotic treatment due to selective 
pressure.  This selective pressure causes the development, acquisition, and spread of the 
resistance gene or factor itself or by specific biochemical mechanism of the resistance 
gene or factor (USDA, 1999).  Moreover, Bach Knudsen (2001) reported that antibiotic 
growth promoters also exert a selective pressure on the commensal microorganisms since 
antibiotics are weakly absorbed in the gastrointestinal tract.  Thus, the bacteria develop 
reduced susceptibility, where it become less susceptible to a particular antibiotic that can 
lead to the development of resistance, and a reduction or elimination in the effectiveness 
of that antibiotic to both animal and human medicine (Yan and Gilbert, 2004).   
 There are many mechanisms in the development of resistance with subtherapeutic 
use of antibiotics.  Hawkey (1998) classified these mechanisms into four basic types: 1) 
modification of the antibiotic, 2) prevention of antibiotic from penetrating the cell wall, 
3) production of an alternative target, and 4) alterations in the primary site (Figure 2.4).  
The first three mechanisms prevent the antibiotic (e.g. β-lactam antimicrobials, 
aminoglycosides and chloramphenicol) from having an effect on the bacteria due to drug 
inactivation, which involves hyperproduction of an enzyme that is unaffected by the 
antibiotic action (McManus, 1997).  Antibiotic resistant bacteria also may alter their 
structure by natural selection, random mutation, and DNA swapping through 
transduction, transformation and transposition, which inhibit the action of antibiotics 
(Food Systems Insider, 2002; McManus, 1997).  Moreover, the action of antibiotics not 
only affects the bacteria or pathogen, but it also affects the entire microflora of the 
gastrointestinal tract creating an imbalance and can lead to the development of resistance.  
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This resistance can be transferred potentially to animals and humans as well (van den 
Bogaard and Stobberingh, 1999).  
Figure 2.4. Four major biochemical mechanisms of antibiotic resistance (Hawkey, 1998). 
 
Alternatives to antibiotics – mechanism and studies 
 Alternatives have been developed and used to replace antibiotic growth promoters 
with the objective of mimicking the effects of antibiotics in growth promotion, by 
altering the proportions of specific gut bacterial species and limiting the numbers of 
unfavorable bacteria while promoting the colonization of more favorable species 
(Verstegen and Williams, 2002; Mathew, 2002).  Moreover, Hardy (2003) proposed three 
distinct approaches to improve animal performance with the use of alternative products.  
These approaches are: 1) providing the optimum conditions for digestive functions by 
supporting the intestinal environment with the nutrients available to the animal, 2) 
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manipulating the microbial population directly, and 3) enhancing the immune system 
with the use of supplements.   
 
Modifying gut acidity with acidifiers 
 Aside from the direct effect on digestive enzyme activities (Mathew, 2002), 
maintaining an optimum acidic pH in the gut is one of the important defenses against 
intestinal colonization by harmful bacteria (Dinsmore et al., 1997).  This may be attained 
with the use of dietary acidifiers (e.g. organic and inorganic acids), which have been used 
primarily in weanling pig diets.  With the reduction of pH in the stomach, both the gastric 
proteolysis and nutrient digestibility would increase and the beneficial bacteria would 
proliferate against the pathogens, thus, making the acidifiers exert some antimicrobial 
activities like that of antibiotics (Close, 2000).  The acids, in particular the organic acids, 
have the ability to change to the dissociated form from its undissociated form (Partanen 
and Mroz, 1999).  The dissociated form of the organic acid is responsible for the 
modification of the pH in the gut, while the undissociated form of the organic acid can 
penetrate the bacterial cell wall leading to the disruption of cellular DNA formation and 
protein synthesis (Hardy, 2003).  Thus, organic acids may improve growth and 
performance by reducing microbial competition with the pig for nutrients, by lowering 
the occurrence of subclinical infections, by lowering the intestinal immune response, and 
by reducing the production of destructive microbial metabolites (Dibner and Buttin, 
2002).  
 Several studies have been performed to evaluate the antimicrobial and growth 
performance effects of acidifiers, mainly organic acids, in the diets of pigs.  Partanen and 
Mroz (1999) summarized the response of dietary organic acids in weaned piglets (Table 
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2.1).  Although no differences were found among the different kinds of organic acids, 
supplementation of dietary organic acids increased average daily bodyweight gain and 
improved the feed:gain ratio as compared to the non-acidified control diet. 
Table 2.1. Response of weaned piglets to dietary organic acids (adapted from 
Partanen and Mroz, 1999). 
 No. of  Range of acid level   
Organic acid Exp. (mequiv/kg) ADGa Feed:gaina
Formic acid and formates 11 46-444 0.269 -0.721 
Fumaric acid 15 86-431 0.409 -0.899 
Citric acid 9 78-391 0.255 -0.829 
a P < 0.04, probability that acidified diets differ from non-acidified control diet. 
A study performed by De Rodas et al. (1995) reported that using a blend of organic and 
inorganic acids at around 3 kg/ton improved daily gains in pigs by 27% during the first 
two wk after weaning.  The addition of 1% citric acid also improved daily gain and feed 
conversion ratio in weanling pigs (Burnell et al., 1988).  In another study, 
supplementation of 1% to 3% fumaric acid to starter diets during the first 3 to 4 wk after 
weaning improved the apparent ileal amino acid digestibilities by 4.9% to 12.8% (Blank 
et al., 1999).  In various studies, the inclusion of organic acids in the diets of pigs reduced 
the coliform incidence in the gastrointestinal tract, scouring, and piglet mortality (Cole et 
al., 1968; Bolduan et al., 1988; Thomlinson and Lawrence, 1981).  However, some 
studies showed negligible effects of adding organic acids on bacterial infection.  A study 
done by Risley et al. (1992) using 1.5% fumaric or citric acid did not change the 
intestinal bacterial populations in piglets.  This variability may be due to the age of pigs, 
amount of milk by-products in the diet, and the presence or absence of antibiotics 
(Holden et al., 2002).  Hardy (2003) further added that the inconsistent results can be 
attributed to the differences in levels and types of organic acids, the acid buffering 
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capacity of the dietary ingredients, and the ability of bacteria to develop an acid 
resistance (Hardy, 2003).  
 
Probiotics and competitive exclusion 
 The gastrointestinal microflora can be modified to improve the health and 
performance of the piglets by minimizing the adverse effects of pathogenic bacteria 
through the increase in the number of favorable organisms in the gut (Hardy, 2002).  This 
alteration of gut microflora can be achieved with the use of probiotics or direct-fed 
microbials, which are live microorganisms added to animal feed to restore the balance of 
microflora in favor of the beneficial microorganisms (Fuller, 1989; Cromwell, 2001).  
Some of the major bacterial organisms used as probiotics are Lactobacilli spp., 
Streptococci spp., Bacillus spp., Bifidobacteria spp., and yeasts (Hardy, 2002).   
Numerous probiotic preparations and cultures are available in the market but to be 
effective in improving the performance of the animal, Collins and Gibson (1999) stated 
that probiotics should 1) exert a beneficial effect on the host, 2) be nonpathogenic and 
nontoxic, 3) contain a large number of viable cells, 4) be capable of surviving and 
metabolizing in the gut, 4) remain viable during storage and use, 5) have good sensory 
properties, and 6) be isolated from the same species as its intended host.  Thus, probiotics 
modify the intestinal microflora by competing against pathogenic bacteria for nutrients in 
the gut, by producing compounds that are toxic to pathogens, and by competing with 
pathogens for binding sites on the intestinal wall (Hentges, 1992).  
 The application of probiotics has been widely used in humans and its gaining 
considerable interest in food-producing animals.  Cromwell (2001) summarized the 
effects of probiotics and antimicrobial agents in the diets of weanling pigs (Table 2.2).  
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Although the addition of promicrobials did not improve growth performance as compared 
to the addition of antimicrobials, it has an additive effect when combined with antibiotics.  
Table 2.2. Effects of promicrobial and antimicrobial agents in starting diets for  
weanling pigsa (adapted from Cromwell, 2001). 
 None Promicrobialsb Antimicrobialsb Both 
Daily gain, gc 247 237 306 310 
Daily feed, gc 467 460 540 550 
Feed:gain, gc 1.92 1.96 1.77 1.75 
a A summary of five experiments involving 764 pigs weaned at 4 weeks of age (7.4 kg 
BW); 4-wk test period. 
b Promicrobials were various combinations of Saccharomyces cerevisiae,
Lactobacillus acidophilus, and Streptococcus faecium. Antimicrobials were a 
mixture of chlortetracycline, penicillin, and sulfamethazine. 
c Effect of antimicrobials (P < 0.001). 
 
However, a study by Fedorka-Cray et al. (1999) showed piglets fed mucosal competitive 
exclusion cultures reduced the incidence of Salmonella compared to control pigs (28% vs 
79%).  In a separate study, the administration of a competitive exclusion culture to 
neonatal pigs reduced mortality and the incidence of fecal shedding and gut colonization 
of E. coli as compared to control pigs (Genovese et al., 2000).  However, the 
improvement in animal performance with the use of probiotics is variable.  Young pigs 
that were given either a low or high dose of Lactobacillus acidophilus L23 improved 
average daily gain compared to a control group without significant differences in feed 
efficiency (Lee et al., 2001).  Kyriakis et al. (1999) evaluated the effect of feeding a 
probiotic to newly-weaned piglets and demonstrated that at a level of 107 viable spores of 
Bacillus licheniformis, the incidence and severity of diarrhea was reduced along with a 
reduction in mortality.  Furthermore, the piglets fed the probiotic had improved growth 
rate and feed efficiency compared to control piglets.  But a study done by De Cupere et 
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al. (1992) reported that supplementation of Bacillus cereus, Lactobacillus spp., and 
Streptococcus faecium did not prevent mortality and clinical symptoms in young pigs 
infected with E.  coli. Average daily gain, feed intakes, and feed efficiency also were not 
improved in pigs fed a Lactobacillus acidophilus culture (Harper et al., 1983).  The 
variability in results may be due to the viability of microbial cultures, strain differences, 
dosage level and frequency of feeding, and medicine interactions (Holden et al., 2002).   
 
Mannan oligosaccharides (MOS) as a performance enhancer alternative 
 Addition of MOS in nursery pig diets has been proven to improve animal 
performance by two mechanisms.  First, MOS prevent bacterial colonization in the gut by 
binding to bacterial cell walls (Spring et al., 2000).  This hinders the bacteria from 
attaching to the epithelial cells of the intestines and the bacteria attached to MOS are 
washed out (Spring et al., 2000; Pettigrew, 2000).  The second mechanism involves the 
enhancement of the immune system by increasing immunoglobulin levels resulting in a 
reduction in mortality (Newman and Newman, 2001; O’Quinn et al., 2001; Pettigrew, 
2000).    
 Pettigrew (2000) reviewed the effects of a commercial mannan oligosaccharide 
(Bio-Mos) in 17 comparisons involving 13 experiments and they are summarized in 
Table 2.3.  There were numerical gains in 14 out of the 17 comparisons and an overall 
improvement in ADG and feed efficiency by 4.4% and 1.47%, respectively.  In other 
studies, addition of MOS in early-weaned pigs improved growth approximately one-half 
of that obtained with high inclusions of copper (Davis et al., 1999; Cromwell, 2001), 
whereas there was no response of MOS addition in weanling pig diets (Davis et al., 2000; 
Cromwell, 2001).  In more recent studies, weanling pigs fed diets with 0.20% Bio-Mos 
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had improved growth performance, but this response was dependent on copper sulfate 
(Davis et al., 2002) or zinc oxide levels in the diet (LeMieux et al., 2003).  Dietary 
supplementation of mannan oligosaccharides also modulated the immune function with 
an increase in IgG levels (White et al., 2002) and a decrease in the percentage of 
neutrophils (Davis et al., 2004). 
Table 2.3. Growth responses to Bio-Mos in starter diets for pigs (adapted from Pettigrew, 2000). 
Authors, Year Reps Bio-Mos ADG %  Feed/gain %  
description     level (%) Ca Bb Diffc Ca Bb Diffc
van der Beke 1997 12 0.2 243 261 7.33 1.90 1.80 -5.26 
Dvorak & Jacques 1998 4 0.2 309 341 10.30d 1.30 1.26 -3.08 
Kumprecht & Zoba 1999 3 0.2 NA NA 8.50    
LeMieux et al.,            
 High Zn 1999 5 0.2-0.3 307 318 3.48f 1.45 1.46 0.34 
LeMieux et al.,            
 Low Zn 1999 5 0.2-0.3 262 291 11.04 1.48 1.46 -1.35 
Stockland, Trial 1 1999 4 0.1 243 258 6.17 1.18 1.20 1.69 
Stockland, Trial 2 1999 5 0.1-0.4 163 189 16.07 1.40 1.25 -11.07 
Stockland, Trial 3 1999 6 varied 418 427 2.18d 1.23 1.27 2.85 
Stockland, Trial 4 1999 6 0.2/0.1 452 439 -2.68 1.24 1.31 5.65 
Brendemuhl and          
 Harvey 1999 4 0.1-0.2 639 649 1.56 1.75 1.69 -3.43 
Davis et al. 1999 18 0.2 402 427 6.30e 1.49 1.41 -5.37e
Harper & Estienne,          
 No antibiotic 2000 5 0.3/0.2 445 450 1.03 1.73 1.72 -0.58 
Harper & Estienne,          
 Mecadox 2000 5 0.3/0.2 490 490 0.00 1.72 1.69 -1.74 
Maxwell et al.,          
 Low Zn 1999 9 0.3/0.2 406 423 4.23 1.47 1.43 -2.72 
Maxwell et al.,          
 High Zn 1999 9 0.3/0.2 446 439 -1.59 1.41 1.39 -1.42 
Maxwell et al.,           
 Low Zn 2000 6 0.2-0.3 413 406 -1.62 1.32 1.37 3.79g
Maxwell et al.,           
 High Zn 2000 6 0.2-0.3 427 437 2.44 1.33 1.31 -1.88 
 
total 112 Means 379 390 4.40 1.46 1.44 -1.47 
a Control. 
b Bio-Mos. 
c Bio-Mos minus control. 
d Statistical significance level, P < 0.01. 
e Statistical significance level, P < 0.04. 
f Bio-Mos by zinc level interaction, P < 0.07. 
g Quadratic effect of Bio-Mos level, P < 0.01. 
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Beta-glucan as an immunomodulator 
 Because piglets at the time of weaning experience great stress in addition to 
having a reduced digestive capacity and underdeveloped immune system, 
supplementation of immune modulators could enhance the immune system of the piglets.  
This effect of immunomodulators on the immune function of the weanling pig, which is 
exposed to various stressors and pathogenic organisms, could decrease the susceptibility 
to diseases and reduce economic loss (Blecha and Charley, 1990).  One of the 
immunomodulators that can be fed to young pigs is beta-glucan.   
 Beta-glucan is a polysaccharide made up of 1,3- and 1,6-glucose linkages that is 
present in some plants (oat and barley bran), fungi (Lentinus edodes), mushrooms 
(Grifola frondosa), and from cell walls of brewers’ and bakers’ yeast (Saccharomyces 
spp.) (Baur and Geisler, 1996; Brown and Gordon, 2003; Tokunaka et al., 2000; Bacon et 
al., 1969; Borek, 2001).  As an immunostimulatory substance, beta-glucan acts through 
the macrophage and eventually produces interleukin-1 thus, enhancing both innate and 
adaptive immune responses of the animal (Hardy, 2003).  In vitro studies have been 
performed using beta-glucan from Grifola frondosa to determine the stimulatory effect 
on macrophages (Adachi et al., 1994; Okazaki et al., 1995).  Results from these studies 
showed that beta-glucan stimulated the macrophages and produced cytokines (e.g. 
interleukin-1, interleukin-6 and tumor necrosis factor alpha).  Beta-glucans also can 
induce the release of nitric oxide.  A study performed by Jung et al. (2004) looked at the 
effects of Saccharomyces cerevisiae beta-glucan in increasing the production of nitric 
oxide and interferon-γ in piglets infected with swine influenza virus.  They found that the 
concentrations of nitric oxide and interferon-γ were significantly higher in infected 
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neonatal pigs supplemented with beta-glucan than the piglets that were infected with the 
virus but were unsupplemented with beta-glucan.  These effects of beta-glucan as 
immunomodulators are affected by their degree of branching, polymer lengths, and 
tertiary structures (Brown and Gordon, 2003), where only those that consist of (1-3)-
linked beta-glucan backbone with (1-6)-linked beta-D-glucopyranosyl units as branches 
would have the immunomodulating capacity (Bohn and BeMiller, 1995).  
 Several experiments have evaluated the effects of beta-glucans on growth 
performance and overall health of pigs.  Dritz et al. (1995) reported that weanling pigs 
fed with 0.025% beta-glucan had an increase in average daily gain and feed intake.  In 
another study, young pigs raised from sows treated with beta-glucan had a higher weight 
gain compared to the control group due to the increase in antibody titer levels in the 
sow’s milk (Decuypere et al., 1998).  Piglets that received beta-glucan, with Lentinus 
edodes as the source, had an increase in villous length and had a lower bacterial load as a 
result of lower turnover rates of the intestinal epithelial cells (van Nevel et al., 2003).  
However, Hiss and Sauerwein (2003) reported in their study that the inclusion of beta-
glucan in the diets of piglets did not influence average daily gain and feed efficiency and 
lymphocyte proliferation indices also were not significantly different from the control 
group.  In finishing pigs, beta-glucan supplementation in the diet did not improve growth 
performance or carcass quality (Fortin et al., 2003).  
 
Non-nutritional strategies and alternative husbandry practices 
 Although the use of antibiotic growth promoters and its alternatives improve the 
performance and health of animals, better feeding strategies, optimum management, and 
environmental controls must also be addressed, especially with the possibility of an 
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antibiotic ban.  Provision of good quality water, maintenance of ambient temperature, and 
implementation of strict biosecurity and hygiene practices can be implemented on 
commercial farms (Hardy, 2002), as well as effective feeding practices, proper animal 
flow (all-in, all-out), and timely vaccination programs would all contribute to 
improvements in animal health and well being (Mathew, 2002; Doyle, 2001).  Genetic 
improvements can also be done by changing the capability of the animal to initiate an 
immune response to infection (Holden et al., 2002).  Furthermore, reliance on antibiotic 
growth promotants can be reduced by appropriate maintenance of ventilation rate and 
stockings rates, and careful record keeping (Doyle, 2001).  Implementation of these 
strategies would result in more-profitable swine farming for the producer and safe, 
healthy food-products for the consumer.  
 
Summary 
 In the event of the ban on the use of antibiotics as growth promoters, the use of 
alternative growth promotants will be of great consideration as a replacement to maintain 
and further improve growth performance and overall health of animals.  However, current 
alternatives that have been studied resulted in inconsistent results.  Thus, the following 
experiments were conducted to evaluate the effects of beta-glucan and other alternatives 











Beta-glucan is commonly derived from the cell wall of baker’s yeast, 
Saccharomyces cerevisiae. As an immunomodulator, it helps boost the immune system 
by stimulating a cascade of pathways that enhance both innate and adaptive immune 
responses (Hardy, 2003).  An active immune system would help the animal fight disease 
challenges, help control clinical infection, and maintain growth processes.   
 Several studies have been performed with weanling pigs using beta-glucan but 
results have been variable on growth and immune parameters.  This may be due to 
differences in the composition and concentration of beta-glucan.  Thus, the objective of 
this experiment was to determine the optimum dose of beta-glucan and its effect on 
growth performance and immune response of weanling pigs.   
 
Materials and Methods 
 One-hundred seventy-six pigs (average initial BW = 5.8 kg) were weaned at 
approximately 21 d and housed (5-6 pigs/pen) in a temperature-controlled nursery rooms 
for 42 d.  Pigs were blocked by weight and randomly allotted to four dietary treatments (8 
pens/trt).  Cornstarch was replaced, as needed, by carbadox (Mecadox®, Pfizer Animal 
Health, New York, NY), or beta-glucan (Dong-Ahm BT, Seoul, South Korea) to provide 
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the four dietary treatments within each phase as follows: 1) negative control (NC), 2) NC 
with 0.25% carbadox, 3) NC with 0.20% beta-glucan and 4) NC with 0.40% beta-glucan.  
All diets were corn-soybean meal-based (Table 3.1) and fed in meal form.  Pigs were fed 
in three dietary phases.  Phase 1 diets (1.60% tLys) were fed from d 0 to d 14 and 
contained dried whey, lactose, spray-dried animal plasma, and fish meal.  Phase 2 diets 
(1.40% tLys) were fed from d 14 to d 28 and contained dried whey, spray-dried blood 
meal and fish meal.  Phase 3 diets (1.20% tLys) were fed from d 28 to 42 and were 
simple corn-soybean meal diets.  Feed and water were provided on an ad libitum basis 
throughout the experiment.  Pigs and feeders were weighed on d 0, 7, 14, 21, 28, 35, and 
42 to determine average daily gain (ADG), average daily feed intake (ADFI), and feed 
efficiency (G:F ratio). 
Blood collection and analysis - Blood was collected from two randomly selected pigs 
(one male and one female) per pen.  Blood samples were taken via jugular venipuncture 
on d 14, 28, and 42 using vacutainer tubes with anticoagulant for hematology, or without 
anticoagulant for C-reactive protein (CRP) determination.  Hematology (white blood 
cells [WBC], lymphocytes, and neutrophils) was performed within an hour after 
collection using colorimetric procedures (ABX Pentra).  The tubes without anticoagulant 
were centrifuged and serum was frozen until CRP determination.  C-reactive protein was 
determined using a colorimetric method (Alfa Wasserman Clinical Analyzer).   
Statistical Analysis – All data were analyzed as a randomized complete block design 
using analysis of variance procedures as described by Steel and Torrie (1997).  The 
model included the effects of replication, treatment, and replication x treatment (error).  
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Treatment means were separated using Least Significant Difference.  The pen served as 
the experimental unit.  
 
Results 
For Phase 1, there were no differences (P > 0.10) in ADG, ADFI, and G:F ratio of 
pigs fed diets containing carbadox or 0.20% beta-glucan compared to pigs fed the 
negative control diet (Table 3.2).  However, pigs fed diets with 0.40% beta-glucan gained 
slower (P < 0.04) and consumed less (P < 0.04) feed as compared with pigs fed carbadox.  
Moreover, pigs fed 0.40% beta-glucan tended to have decreased ADG (P < 0.09) and 
ADFI (P < 0.04) as compared with pigs fed either 0.20% beta-glucan or the negative 
control diet.  Although G:F did not differ (P > 0.10) among the dietary treatments, pigs 
fed 0.40% beta-glucan had the poorest feed efficiency.  In Phase 2, pigs fed diets with 
carbadox tended to have greater ADG (P < 0.10) than pigs fed either 0.40% beta-glucan 
or the negative control diet.  The growth performance response of pigs fed the diet with 
0.20% beta-glucan was intermediate between pigs fed either carbadox or the negative 
control diet.    
 For Phases 1 and 2 combined, pigs fed diets with 0.20% beta-glucan had similar 
(P > 0.10) ADG, ADFI, and G:F as those pigs fed either carbadox or the negative control 
diet.  Incorporation of 0.40% beta-glucan in the diet of weanling pigs resulted in lower (P 
< 0.02) ADG and ADFI as compared with pigs fed carbadox.  Pigs supplemented with 
0.20% beta-glucan tended to have greater ADG (P < 0.08) and greater ADFI (P < 0.03) 
than pigs fed diets with 0.40% beta-glucan.  Numerically, pigs fed carbadox had the 
greatest growth performance.  The growth response of pigs fed 0.20% beta-glucan was 
intermediate to that of pigs fed the negative control diet and those fed carbadox. 
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There were no differences (P > 0.10) in ADG, ADFI and G:F ratio during Phase 3 
for all treatment groups.  Overall (in all three phases), there were no differences (P > 
0.10) in ADG, ADFI and G:F of pigs fed diets containing carbadox or 0.20% beta-glucan.  
Pigs fed diets with 0.40% beta-glucan had lower (P < 0.05) ADG compared with pigs fed 
diets containing carbadox although they did not differ (P > 0.10) in G:F.  At the same 
time, growth performance was not different (P > 0.10) for pigs fed 0.20% beta-glucan 
compared with pigs fed the negative control diet.  Although not statistically significant, 
ADG, ADFI, and G:F were greater for pigs fed carbadox than for pigs fed 0.20% beta-
glucan or the negative control diet.  In addition, the response of pigs to 0.20% beta-
glucan was intermediate to that of pigs fed carbadox or the negative control diet.  
 Table 3.3 shows the hematology values and CRP levels, with some differences 
noted among treatment groups.  Pigs fed the negative control diet or those with carbadox 
had lower (P < 0.10) WBC on d 14 and 28.  However, WBC was increased (P < 0.10) 
with beta-glucan supplementation on d 14.  By d 28, WBC was greater (P < 0.10) for pigs 
fed beta-glucan compared to pigs fed carbadox.  No differences (P > 0.10) were noted on 
d 42. Lymphocyte count on d 14 tended to follow a similar trend as WBC.  Pigs fed beta-
glucan tended to have higher (P < 0.10) lymphocytes on d 14, followed by carbadox and 
then pigs fed the negative control diet.  There were no differences (P > 0.10) in 
lymphocytes on d 28 and 42.  Neutrophils followed a similar trend in that pigs fed 0.40% 
beta-glucan tended to have the greatest (P < 0.10) neutrophils.  The levels of CRP were 
lower (P < 0.10) on d 14 for pigs fed diets containing carbadox or 0.20% beta-glucan 
compared to those in the negative control group and 0.40% beta-glucan.  There were no 
differences in CRP on d 14 and 28 and CRP tended to increase with age.  
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Discussion 
Schoenherr et al. (1994) performed an experiment evaluating the effects of 
feeding different levels of beta-glucan on growth performance of weanling pigs (19 d of 
age).  They found no improvements in growth parameters among the different levels of 
beta-glucan (0, 0.025, 0.05, 0.075, 0.10, and 0.125% beta-glucan) during the first 2 wk 
postweaning, but on d 34 after weaning, beta-glucan improved (P < 0.01) overall ADG 
(0.498, 0.548, 0.528, 0.538, 0.507, and 0.495 kg/d, respectively).  With these results, they 
concluded that to maximize the growth performance of pigs in the nursery period, the 
optimum inclusion level of beta-glucan in diets was between 0.025% and 0.05%.  In 
another study, Dritz et al. (1995) evaluated the influence of dietary beta-glucan on growth 
performance of weanling pigs.  Pigs (14-21 d of age) were fed diets with different levels 
of beta-glucan (0, 0.025, 0.05%, and 0.10% beta-glucan).  They reported that the addition 
of 0.10% beta-glucan decreased growth performance of weanling pigs during the first 7 d 
post-weaning.  However, they found that 0.025% inclusion of beta-glucan increased 
ADG of pigs at d 28 after weaning due to increased feed intake.  The addition of 0.05% 
beta-glucan also increased ADG of pigs but was lower as compared to 0.025% beta-
glucan.  Thus, they suggested that the optimum inclusion level of beta-glucan to improve 
growth performance of weanling pigs was at 0.025% of the diet.   
The present experiment used beta-glucan at 0.20% inclusion level and the ADG 
of weanling pigs was not decreased, although it was at the 0.40% inclusion level.  This 
could be attributed to a lower feed intake exhibited by pigs fed 0.40% beta-glucan as 
compared to pigs fed 0.20% beta-glucan.  Moreover, since beta-glucan is being 
recognized by the pig’s immune system as foreign, it generated an immune response, 
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which is energetically costly (Demas et al, 1997).  In their study, Demas et al. (1997) 
reported that mice injected with an antigen had higher (P < 0.05) O2 consumption, than 
mice injected with saline, and the authors suggested that the increase in O2 consumption 
indicates increased metabolic heat production, which could have affected feed intake.  
There were minimal differences in growth parameters of pigs fed with either the negative 
control diet, carbadox treated diet, or 0.20% beta-glucan treated diet, except in Phase 2.  
However, ADG and G:F were consistently higher in pigs fed diets with carbadox than 
pigs fed diets with either 0.20% beta-glucan or the negative control diet.  Moreover, the 
ADG of pigs fed 0.20% beta-glucan was intermediate between the pigs fed carbadox and 
negative control diets.  In all three phases, ADG was improved by 4.9% for pigs treated 
with carbadox.  This response was much lower than the average improvement in growth 
performance attributed to antibiotic supplementation to weanling pig diets (4.9% vs 
16.4%) as reported by Cromwell (2001).  However, the response to antibiotic in research 
facilities is often much less than that observed in commercial facilities (16.9% vs 28.4% 
for ADG; 7.0% vs 14.5% for feed/gain) due to differences in disease level (Cromwell, 
2001).  The average improvement in ADG due to beta-glucan was 1.8%, which was 
about half the response of carbadox.  
Hardy (2003) stated that beta-glucan stimulates the macrophages to produce 
cytokines that activate lymphocytes.  As constituents of white blood cells, lymphocytes 
and neutrophils function in the innate and acquired immunity of pigs by producing 
inflammatory response mediators, phagocytosis and destruction of bacteria (Johnson et 
al., 2001) and their numbers are increased during immune reaction to stress and disease 
conditions.  This was demonstrated in this experiment, where pigs fed diets with 0.40% 
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beta-glucan had the highest values of WBC and lymphocytes on d 14, 28 and 42 and 
neutrophils on d 14.  However, in a study by Dritz et al. (1995), the authors reported that 
neither the addition of 0.025% nor 0.05% beta-glucan influenced the neutrophils count or 
macrophage function.  The differential response in WBC in our study as compared to that 
of Dritz et al. (1995) could be attributed to differences in the dosage levels of beta-glucan 
that were used.   
C-reactive protein (CRP) is one of the major acute phase proteins in swine and its 
concentration is increased rapidly in response to infection, inflammation, or trauma 
(Chen et al., 2003; Eckersall et al., 1996).  Moreover, CRP levels are increased in porcine 
serum within the first 5 days after challenge but subsequently decreased to normal levels 
thereafter (Heegaard et al., 1998; Eckersall et al., 1996).  In this experiment, CRP levels 
were the lowest for pigs fed either carbadox or 0.20% beta-glucan diets, implying that 
those pigs were healthier than pigs fed either 0.40% beta-glucan diet or the negative 
control diet.  However, CRP levels in pigs might be more important as a stress indicator 
(Burger et al., 1998) rather than health status (Burger et al., 1992).  In a similar study by 
Dritz et al. (1995), they determined the influence of adding two levels of beta-glucan on 
the concentration of plasma haptoglobin, which is another major acute phase protein in 
swine.  They reported that pigs fed either 0.025% or 0.05% beta-glucan had lower plasma 
haptoglobin concentrations, which translated to greater ADG, than pigs fed the control 
diets on d 14.  In this experiment, pigs fed either 0.20% beta-glucan or carbadox had 
lower CRP levels and higher ADG than pigs fed either 0.40% beta-glucan or the negative 




The inclusion of 0.20% beta-glucan in the diets of weanling pigs appears to have 
a growth performance response that is intermediate to that of carbadox inclusion or 
feeding a negative control diet.  Moreover, the addition of beta-glucan in the diet 
increased WBC, lymphocyte and neutrophil count, and decreased concentrations of CRP 
as compared to non-addition.  However, the addition of 0.40% beta-glucan depressed 
growth performance of pigs.   
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Table 3.1. Composition of diets in Experiment 1 (as fed-basis). 
Ingredient, % Phase 1  Phase 2  Phase 3 
Corn grain 28.23  48.79  56.58 
Soybean meal (48% CP) 22.91  28.15  34.86 
Whey, dried 20.00  10.00  0 
Lactose 10.00  0  0 
Plasma, spray-dried 6.00  0  0 
Blood cells, spray dried 0  2.50  0 
Fish meal, menhaden 5.00  2.50  0 
Soybean oil 5.00  5.00  5.00 
DL-methionine 0.22  0.06  0.00 
Dicalcium phosphate 0.60  1.12  1.33 
Limestone, ground 0.87  0.80  0.90 
Salt 0.35  0.25  0.50 
Trace mineral mixa 0.15  0.15  0.15 
Vitamin mixb 0.25  0.25  0.25 
Ethoxyquin 0.03  0.03  0.03 
Cornstarch c 0.04  0.04  0.04 
Calculated Analysis:      
ME, kcal/kg 3,506  3,534  3,549 
Lysine, % 1.60  1.40  1.20 
Ca, % 0.95  0.85  0.75 
P, % 0.75  0.70  0.65 
a Supplied per kg of diet: 16.5 mg of Cu (copper sulfate); 165 mg of Fe (ferrous 
sulfate); 0.30 mg of I (calcium iodate); 40 mg of Mn (manganese oxide); 0.30 mg of 
Se (sodium selenite); and 165 mg of Zn (zinc oxide). 
b Supplied per kg of diet: 11,013 IU of vitamin A; 1,652 IU of vitamin D3; 44 IU of 
vitamin E; 4.4 mg of vitamin K (menadione activity); 55 mg of niacin; 10 mg of 
riboflavin; 33 mg of pantothenic acid (D-calcium pantothenate); and 44 µg of
vitamin B12.c Cornstarch (CS) was replaced by carbadox or beta-glucan, as needed, to provide the 
treatments within each phase as follows: 1) negative control (0.40% CS), 2) 0.25% 
carbadoxd + 0.15% CS, 3) 0.20% beta-glucan + 0.20% CS, and 4) 0.40% beta-glucan. 
d Provided 55 mg of carbadox per kg of complete feed. 
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Table 3.2. Growth performance of weanling pigs (Exp. 1) a.
Treatmentb
Item NC AB 0.20% BG 0.40% BG SE 
Number of pigs 44 44 44 44  
Initial weight, kg 5.83 5.82 5.81 5.82 0.03 
Final weight, kg 19.54cd 20.47c 20.00cd 19.38d 0.37 
Phase 1      
 ADG, kg 0.172c 0.177c 0.176c 0.150d 0.01 
 ADFI, kg 0.275c 0.274c 0.278c 0.241d 0.01 
 G:F 0.631 0.652 0.623 0.622 0.03 
Phase 2      
 ADG, kg 0.360d 0.392c 0.375cd 0.357d 0.01 
 ADFI, kg 0.520cd 0.556c 0.550cd 0.516d 0.02 
 G:F 0.686 0.701 0.681 0.697 0.02 
Phases 1 & 2      
 ADG, kg 0.266cd 0.285c 0.275c 0.252d 0.01 
 ADFI, kg 0.393cd 0.411c 0.407c 0.371d 0.01 
 G:F 0.673 0.689 0.671 0.679 0.01 
Phase 3      
 ADG, kg 0.455 0.462 0.456 0.450 0.02 
 ADFI, kg 0.790 0.772 0.782 0.772 0.02 
 G:F 0.578 0.602 0.587 0.587 0.02 
Overall       
 ADG, kg 0.327cd 0.343c 0.333cd 0.316d 0.01 
 ADFI, kg 0.526 0.534 0.532 0.505 0.01 
 G:F 0.620 0.645 0.625 0.627 0.01 
a Least square means for 8 pens (5-6 pigs/pen) per treatment. 
b NC = negative control, AB = NC + carbadoxe, 0.20% or 0.40% BG = NC + 0.20% 
or 0.40% beta-glucan. 
c,d Within a row, means without a common superscript letter differ (P < 0.10). 
e Provided 55 mg of carbadox per kg of complete feed. 
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Table 3.3. Hematology and serum CRP of weanling pigs (Exp. 1)a.
Treatmentb
Item NC AB 0.20% BG 0.40% BG SE 
Number of pigs 16 16 16 16  
WBCc, 103/mm3
d 14 16.17d 15.61d 17.01de 19.11e 1.17 
 d 28 14.36de 12.94d 15.59e 15.73e 0.87 
 d 42 17.73 17.41 19.66 19.94 1.21 
Lymphocytesc, absolute      
 d 14 8.59d 9.34de 9.73de 10.56e 0.55 
 d 28 8.08 8.55 9.67 8.92 0.76
d 42 12.39 12.51 13.41 12.45 0.95 
Neutrophilsc, absolute      
 d 14 6.71de 5.53d 6.41de 7.52e 0.73 
 d 28 5.55e 3.72d 5.16e 6.01e 0.40 
 d 42 4.31d 3.90d 5.06d 6.29e 0.49 
C-reactive protein, mg/dL      
 d 14 7.89d 4.75e 3.44e 5.82d 1.01 
 d 28 6.33 6.87 6.05 6.76 0.59
d 42 8.78 8.44 8.62 9.50 0.58
a Least square means for 8 pens (2 pigs/pen) per treatment. 
b NC = negative control, AB = NC + carbadoxf, 0.20% or 0.40% BG = NC + 0.20% or 
0.40% beta-glucan. 
c Normal ranges: WBC: 11-22 x 103/mm3; Lymphocytes:6-10; Neutrophils: 4.0-7.5 
(CCAC, 1993). 
d,e Within a row, means without a common superscript letter differ (P < 0.10). 






Effects of beta-glucan and antibiotics on growth performance  
and carcass traits of weanling and finishing pigs 
 
Introduction 
 Results observed in Experiment 1 suggested that growth performance of weanling 
pigs fed 0.20% beta-glucan was intermediate to that of pigs fed carbadox or a negative 
control diet.  In addition, carbadox addition consistently resulted in the greatest 
improvement in growth performance among the dietary treatments used.  However, 
inclusion of 0.40% beta-glucan reduced growth performance of pigs as compared to pigs 
fed the negative control diet.  Previous studies also indicated that higher inclusion levels 
of beta-glucan may depress growth performance.  Yet, results of Experiment 1 suggested 
that beta-glucan can be added in the diet up 0.20% without reduction in growth 
performance. 
A study performed by Fortin et al. (2003) evaluated the effects of beta-glucan 
supplementation to the diet on the growth performance of growing-finishing pigs.  These 
authors reported that beta-glucan did not improve growth performance or carcass quality.  
Moreover, several studies have been performed to evaluate the effect of combining 
antimicrobial agents with alternatives on growth performance of weanling and finishing 
pigs.  Thus, this experiment was performed to determine the effects of beta-glucan and 
antibiotics on growth performance and carcass traits of weanling and finishing pigs, and 
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also to determine if an interaction exists between the inclusion of beta-glucan and 
antibiotic in the diet.   
 
Materials and Methods 
A total of one-hundred forty pigs (average initial BW = 5.4 kg) was weaned at 
approximately 20 d of age for the nursery study.  Pigs were blocked by weight and 
allotted randomly to four dietary treatments (6 pens/trt) in a 2 x 2 factorial design with 
two levels of carbadox supplementation (0 vs 0.25%) and two levels of beta-glucan (0 vs 
0.20%).  All diets were corn-soybean meal-based (Table 4.1) and fed in meal form.  Pigs 
were fed in three dietary phases.  Phase 1 diets (1.60% tLys) were fed from d 0 to d 14 
and contained dried whey, lactose, spray-dried animal plasma, and fish meal.  Phase 2 
diets (1.40% tLys) were fed from d 14 to d 28 and contained dried whey, spray-dried 
blood meal, and fish meal.  Phase 3 diets (1.20% tLys) were fed from d 28 to 42 and were 
simple corn-soybean meal diets.  Cornstarch was replaced, as needed, by carbadox 
(Mecadox®, Pfizer Animal Health, New York, NY), or beta-glucan (Dong-Ahm BT, 
Seoul, South Korea) to provide the four dietary treatments.  Pigs were housed (5-6 
pigs/pen) in a temperature-controlled room and were allowed to have ad libitum access to 
feed and water throughout the experiment.  Pigs and feeders were weighed on d 0, 7, 14, 
21, 28, 35, and 42 to determine average daily gain (ADG), average daily feed intake 
(ADFI), and feed efficiency (G:F ratio).  
Following the nursery phase, the experiment was continued to the growing-
finishing phase.  Pigs were fed one week of their respective diets before being transferred 
to the finisher room.  Four pigs from each nursery pen were randomly chosen, allotted to 
pens, and fed the same four dietary treatments in a 2 x 2 factorial design.  In the finisher 
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phase, carbadox was replaced by chlortetracycline (0.10%).  Dietary treatments (Table 
4.1) were also fed in three dietary phases (Phase 1, initial weight in the finisher to 50 kg; 
Phase 2, 50 kg to 77 kg; Phase 3, 77 kg to 105 kg BW) and contained 1.05%, 0.90% and 
0.75% tLys, respectively.  All diets were corn-soybean meal-based and fed in meal form.  
Pigs and feeders were weighed every two weeks to determine rate and efficiency of gain 
until the pigs reached approximately 105 kg.  At 105 kg, two pigs per pen were 
transported to a commercial packing plant, humanely slaughtered, and the carcasses were 
split along the dorsal midline, weighed and placed in a chiller overnight.  The following 
day, carcasses were ribbed and 10th rib fat depth and longissimus muscle area (LMA) 
were measured.  Using these measures, the percentage of lean in the carcass was 
calculated according to NPPC (2001).   
Statistical Analysis – Data were analyzed as a 2 x 2 factorial arrangement in a 
randomized complete block design using procedures described by Steel and Torrie 
(1997).  The main effects of antibiotic, beta-glucan and their interaction were tested using 
orthogonal contrasts.  The pen served as the experimental unit.   
 
Results 
Nursery phase – There were no interactions (P > 0.10) between carbadox or beta-glucan 
inclusion in the nursery phase (Table 4.2).  In Phase 1, carbadox inclusion improved (P < 
0.04) ADG, but had no effect on ADFI and G:F, whereas the inclusion of beta-glucan 
tended to improve (P < 0.07) G:F.  For Phase 2, the inclusion of carbadox improved 
ADG, and G:F (P < 0.02), and ADFI (P < 0.07).  On the other hand, beta-glucan 
inclusion tended to improve (P < 0.10) G:F of pigs.  For Phases 1 and 2 combined, beta-
glucan and carbadox inclusion improved (P < 0.04) G:F.  The ADG of pigs was increased 
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(P < 0.01) with carbadox addition to the diets, and inclusion of beta -glucan tended to 
improve (P < 0.10) ADG of pigs, as well.  Furthermore, pigs fed carbadox consumed 
more (P < 0.03) feed.  In Phase 3, ADG, ADFI, and G:F of pigs were not improved (P > 
0.10) with addition of carbadox in the diet.  However, beta-glucan tended to increase (P < 
0.10) ADG of pigs although no improvements (P > 0.10) were seen in ADFI and G:F.  
Overall, carbadox and beta-glucan increased (P < 0.05) ADG of pigs.  In addition, 
carbadox increased (P < 0.05) feed intake of pigs.  However, the inclusion of either beta-
glucan or carbadox in the diet had no effect (P > 0.10) on G:F of weanling pigs.  Addition 
of either beta-glucan or carbadox increased (P < 0.04) the final weights of the pigs. 
Finisher phase – During the finisher phase, there were no interactions (P > 0.10) 
between chlortetracycline and beta-glucan except on overall ADG (P < 0.06) (Table 4.3).  
In Phase 1, inclusion of chlortetracycline improved (P < 0.03) G:F of pigs while beta-
glucan tended to improve (P < 0.07) G:F.  However, neither the addition of beta-glucan 
nor chlortetracycline improved (P > 0.10) ADG or ADFI of pigs.  For Phase 2, there was 
no effect (P > 0.10) of adding beta-glucan or chlortetracycline on growth performance of 
pigs.  In Phase 3, beta-glucan inclusion in the diets of pigs tended to increase (P < 0.09) 
ADG and ADFI but did not improve G:F.  Overall, growth parameters were not affected 
by the inclusion of either beta-glucan or chlortetracycline in the diet.  However, pigs fed 
beta-glucan numerically had the greatest ADG, followed by pigs fed carbadox, and then 
pigs fed the combination of beta-glucan and carbadox.  The G:F was also the highest in 
pigs fed beta-glucan, followed by pigs fed the combination of beta-glucan and carbadox, 
and then pigs fed carbadox.  The inclusion of beta-glucan in the diets tended to improve 
(P < 0.08) the final weight of finishing pigs while the inclusion of chlortetracycline in the 
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diet had no effect (P > 0.10) on the final weight.  Numerically, pigs fed the combination 
of beta-glucan and carbadox had the highest market weight (110.51 kg), followed by pigs 
fed beta-glucan (109.30 kg), and then pigs fed carbadox (108.01 kg). 
Overall and carcass traits – For the entire growing period (Table 4.4; nursery to 
finishing), the inclusion of beta-glucan increased (P < 0.04) ADG of pigs while antibiotic 
addition had no effect (P > 0.10) on ADG, ADFI, and G:F of pigs.  For the carcass traits 
(Table 4.4), the inclusion of antibiotics in the diet tended to reduce (P < 0.06) 10th rib 
backfat, although the combination of beta-glucan and carbadox produced the thinnest 10th 
rib backfat (2.12 cm).  The LMA of pigs was not affected with either beta-glucan or 
carbadox inclusion in the diet, although pigs fed the combination of beta-glucan and 
carbadox had the greatest LMA (44.16 cm2).  Fat-free lean percentage also followed a 
similar trend as 10th rib backfat.  Antibiotic addition improved (P < 0.05) the percentage 
fat-free lean but the combination of beta-glucan and carbadox had the highest fat-free 
lean percentage (52.4%).  Overall, the inclusion of beta-glucan in the diet (alone or in 
combination with antibiotic) minimally affected (P > 0.10) the carcass traits measured.   
 
Discussion 
 Based on the results of the first experiment, the addition of 0.40% beta-glucan in 
diets of weanling pigs was not as effective as the inclusion of 0.20% beta-glucan; thus, 
0.20% beta-glucan was used in this experiment.  Several studies have been performed to 
evaluate the effects of antimicrobial agents and alternatives on growth performance of 
weanling and growing-finishing pigs.  One such alternative is mannan oligosaccharides 
(MOS).   
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Mannan oligosaccharides act as a growth promoter by preventing bacterial 
colonization in the gut and by enhancing the immune system (Pettigrew, 2000).  Harper 
and Estienne (2000) evaluated the effect of carbadox (0 vs 55 ppm) and MOS (0 vs 
0.30% for wk 1 and 0.20% for wk 2-5) as growth promoters for weanling pigs (24 d of 
age).  They found no interactions of feeding the two additives for the duration of the trial.  
Mannan oligosaccharides inclusion also did not influence growth performance for the 
entire study.  However, the addition of carbadox improved growth rate and increased feed 
intake by wk 3.  In another study by LeMieux et al. (2003), the effects of MOS (0 vs 
0.20%) and supplemental zinc oxide (0 vs 3,000 ppm) on growth performance of 
weanling pigs were inconsistent.  In a 3-wk study, the addition of MOS improved overall 
ADG and G:F of pigs without zinc oxide (ZnO), but these responses were decreased with 
added ZnO in the diet.  In 4-wk study (Exp. 1 and 2), inclusion of ZnO increased ADG 
and ADFI.  The addition of MOS decreased ADG and G:F, but these responses were 
increased when ZnO was included in the diet.  A study by Davis et al. (2002) determined 
the effect of MOS (0 vs 0.20%) and copper sulfate (0 vs 175 and 125 ppm) on growth 
performance of weanling and finishing pigs.  In the 38 d nursery study, pigs fed either 
supplemental copper sulfate or MOS had greater overall ADG and G:F than pigs fed a 
basal diet without supplemental copper sulfate or MOS.  In the grow-finish stage, 
addition of supplemental copper sulfate increased overall ADG, ADFI, and G:F, while 
MOS addition only improved overall ADG.  However, growth performance of pigs was 
reduced when MOS was added to diet containing 125 ppm supplemental copper sulfate. 
It has been documented that the addition of antibiotics in nursery pig diets 
improves growth performance and reduce mortality and morbidity (Cromwell, 2002).  
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Results of present experiment revealed that pigs fed nursery diets containing either 
carbadox or beta-glucan generally had higher weight gain and better overall feed 
efficiency than those pigs fed the negative control diet.  These results were again similar 
with previous studies (Dritz et al., 1995; Schoenherr et al., 1994), where pigs fed either 
0.025% or 0.05% beta-glucan had greater growth performance response than pigs fed the 
control diet without beta-glucan.  Between the two additives, pigs fed carbadox had a 
greater response than pigs fed beta-glucan, as has been shown in MOS studies.  Similarly, 
in the two experiments that LeMieux et al. (2003) conducted, weanling pigs fed diets 
supplemented with ZnO had the highest overall ADG as compared to pigs fed 0.20% 
MOS (366 vs 308 in Exp. 1; 365 vs 308 in Exp. 2).  However, pigs fed carbadox and 
beta-glucan combined numerically had the greatest overall ADG and G:F among the 
dietary treatments used in our study. 
 There were only minimal improvements on growth performance associated with 
chlortetracycline or beta-glucan supplementation to the diets of pigs in the growing-
finishing stage.  Addition of beta-glucan only influenced growth performance of pigs in 
Phase 3.  The response was also similar between chlortetracycline and beta-glucan.  
Davis et al. (2002) reported that pigs fed ZnO had higher ADG and G:F than pigs fed 
MOS or a combination of MOS and ZnO (1.100, 1.067, and 1.045 kg/d, respectively; 
0.344, 0.329, and 0.328, respectively).  Furthermore, Fortin et al. (2003) reported that the 
inclusion of beta-glucans from oats at different levels (1.6% to 4.1%) did not improve the 
growth performance of pigs as compared to the control diet. 
The addition of beta-glucan did not influence the carcass traits of pigs. Similarly, 
Fortin et al. (2003) reported that pigs fed a control diet, or 1.6% or 4.1% beta-glucan had 
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similar fat thickness and longissimus muscle area.  On the other hand, inclusions of 
antibiotic reduced 10th rib fat and increased fat-free lean percentage.  Stahly et al. (1996) 
hypothesized that the addition of carbadox in the diet improves muscle growth due to the 
production of a growth-promoting factor and/or the reduction of cytokines and other 
inhibitory factors.  They further reported that the inclusion of carbadox in diets of grow-
finish pigs resulted in higher weight gain and better feed efficiency, lower backfat 
thickness, and greater loin eye area as compared to non-inclusion.  These findings agree 
with the results of our study, where pigs fed chlortetracycline had lower backfat and 
higher fat-free lean percentage than pigs fed the negative control diet (2.20 cm vs 2.37 
cm backfat; 52.1% vs 51.0% fat-free lean).  
 
Conclusions 
Overall, the addition of either beta-glucan or carbadox in the diet improved the 
growth performance response of weanling and growing-finishing pigs.  Beta-glucan 
slightly improved ADG in all phases of nursery and finisher stages as compared with the 
other dietary treatments.  No significant interactions were found in combining beta-
glucan and carbadox in the diet.   
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Corn grain 28.17 48.74 56.53  65.18 70.86 76.49 
Soybean meal (48% CP) 22.91 28.15 34.86  29.16 23.70 18.25 
Whey, dried 20.00 10.00      
Lactose 10.00 0      
Plasma, spray-dried 6.00 0      
Blood cells, spray dried 0 2.50      
Fish menhaden meal 5.00 2.50      
Soybean oil 5.00 5.00 5.00  3.00 3.00 3.00 
DL-methionine 0.22 0.06      
Dicalcium phosphate 0.60 1.12 1.33  0.85 0.89 0.65 
Limestone, ground 0.87 0.80 0.90  0.96 0.70 0.76 
Salt 0.35 0.25 0.50  0.25 0.25 0.25 
Trace mineral mixa 0.15 0.15 0.15  0.15 0.15 0.15 
Vitamin mixbc 0.25 0.25 0.25  0.15 0.15 0.15 
Ethoxyquin 0.03 0.03 0.03     
Cornstarchd 0.45 0.45 0.45  0.30 0.30 0.30 
Calculated Analysis:        
ME, kcal/kg 3,506 3,534 3,550  3,479 3,488 3,497 
Lysine, % 1.60 1.40 1.20  1.05 0.90 0.75 
Ca, % 0.95 0.85 0.75  0.65 0.55 0.50 
P, % 0.75 0.70 0.65  0.55 0.50 0.45 
Analyzed Composition:        
Crude Protein (as fed), % 23.38 22.29 20.83  19.04 17.67 12.75 
a Supplied per kg of diet: 16.5 mg of Cu (copper sulfate); 165 mg of Fe (ferrous sulfate), 
0.30 mg of I (calcium iodate); 40 mg of Mn (manganese oxide); 0.30 mg of Se (sodium 
selenite); and 165 mg of Zn (zinc oxide). 
b Supplied per kg of diet in the nursery phase: 11,013 IU of vitamin A; 1,652 IU of 
vitamin D3; 44 IU of vitamin E; 4.4 mg of vitamin K (menadione activity); 55 mg of 
niacin; 10 mg of riboflavin; 33 mg of pantothenic acid (D-calcium pantothenate); and 44 
µg of vitamin B12.c Supplied per kg of diet in the finisher phase: 6,608 IU of vitamin A; 991 IU of vitamin 
D3; 26.4 IU of vitamin E; 2.6 mg of vitamin K (menadione activity); 33 mg of niacin; 6 
mg of riboflavin; 20 mg of pantothenic acid (D-calcium pantothenate); and 26.4 µg of 
vitamin B12.d Within each nursery phase, cornstarch (CS) was replaced with either 0.20% beta-glucan or 
0.25% antibiotic to provide the dietary treatments: 1) 0.45% CS, 2) 0.25% carbadoxg + 0.20%
CS, 3) 0.20% beta-glucan + 0.25% CS, and 4) 0.20% beta-glucan plus 0.25% carbadox. 
e Finisher Phase 1 was from the initial weight in the finisher to 50 kg; Phase 2 was from 50 to 
77 kg; and Phase 3 was from 77 kg to market weight (105 kg). 
f Dietary treatments during the grower-finisher phase were similar to the nursery phase with 
the exception that chlortetracyclineg (0.10%) was used in place of carbadox 
g Provided 55 mg of carbadox per kg of complete feed in the nursery phase and 110 mg of 
chlortetracycline per kg of complete feed in the finisher phase. 
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Table 4.2. Growth performance of pigs during the nursery phase (Exp. 2)a.
Treatment     
beta-glucan, %     
0 0 0.2 0.2  P < : 
carbadoxb ABc BGd ABxBG 
Item - + - + SE effect effect
Number of pigs 35 35 35 35     
Initial weight, kg 5.38 5.36 5.42 5.38 0.02 0.33 0.19 0.65 
Final weight, kg 19.23 19.91 19.6 20.56 0.23 0.01 0.04 0.56 
Phase 1         
 ADG, kg 0.145 0.154 0.149 0.169 0.01 0.04 0.2 0.46 
 ADFI, kg 0.218 0.233 0.221 0.233 0.01 0.13 0.86 0.86 
 G:F 0.665 0.666 0.674 0.724 0.02 0.17 0.07 0.19 
Phase 2         
 ADG, kg 0.343 0.385 0.361 0.387 0.01 0.01 0.35 0.47 
 ADFI, kg 0.509 0.548 0.528 0.53 0.01 0.07 0.96 0.11 
 G:F 0.673 0.697 0.687 0.733 0.01 0.02 0.1 0.44 
Phases 1 & 2        
 ADG, kg 0.244 0.27 0.255 0.278 0.01 0.01 0.1 0.78 
 ADFI, kg 0.363 0.391 0.374 0.381 0.01 0.03 0.91 0.19 
 G:F 0.672 0.69 0.685 0.73 0.01 0.02 0.04 0.27 
Phase 3         
 ADG, kg 0.501 0.5 0.503 0.528 0.01 0.2 0.1 0.14 
 ADFI, kg 0.803 0.826 0.819 0.846 0.02 0.14 0.28 0.9 
 G:F 0.624 0.605 0.617 0.626 0.01 0.64 0.54 0.24 
Overall         
 ADG, kg 0.33 0.346 0.338 0.361 0.01 0.01 0.05 0.55 
 ADFI, kg 0.51 0.536 0.522 0.536 0.01 0.05 0.48 0.52 
 G:F 0.646 0.646 0.65 0.675 0.01 0.22 0.13 0.22 
a Least square means for 6 pens (5-6 pigs/pen) per treatment. 





Table 4.3. Growth performance of pigs during the growing-finishing phase  
(Exp. 2)a.
Treatment     
beta-glucan, %     
0 0 0.20 0.20 P < :
chlortetracyclineb ABd BGe ABxBG
Item - + - + SE effect effect
Initial weight, kg 22.11 23.668 22.97 24.52 0.34 0.01 0.02 0.98 
Final weight, kg 102.67 108.01 109.30 110.51 2.43 0.20 0.08 0.41 
Phase 1c
ADG, kg 0.724 0.726 0.726 0.724 0.02 0.99 0.99 0.92 
 ADFI, kg 1.573 1.630 1.512 1.585 0.06 0.28 0.38 0.90 
 G:F 0.461 0.446 0.481 0.457 0.01 0.03 0.07 0.60 
Phase 2c
ADG, kg 0.742 0.807 0.803 0.823 0.04 0.25 0.29 0.54 
 ADFI, kg 2.114 2.265 2.211 2.347 0.10 0.19 0.40 0.94 
 G:F 0.351 0.357 0.361 0.353 0.01 0.86 0.74 0.46 
Phase 3c
ADG, kg 0.751 0.803 0.849 0.813 0.03 0.79 0.08 0.15 
 ADFI, kg 2.549 2.641 2.796 2.684 0.08 0.90 0.09 0.22 
 G:F 0.295 0.303 0.303 0.305 0.01 0.56 0.57 0.70 
Overall          
 ADG, kg 0.738 0.776 0.794 0.768 0.02 0.73 0.15 0.06 
 ADFI, kg 2.199 2.210 2.219 2.222 0.06 0.46 0.38 0.49 
 G:F 0.349 0.351 0.358 0.353 0.01 0.85 0.34 0.57 
a Least square means for 6 pens (4 pigs/pen) per treatment. 
b Provided 110 mg of chlortetracycline per kg of complete feed. 
c Finisher Phase 1 was from the initial weight in the finisher to 50 kg; Phase 2 was from 




Table 4.4. Growth performance and carcass traits of pigs for the overall 
experiment (Exp. 2)a.
Treatment     
beta-glucan, %     
0 0 0.20 0.20 P < :
antibioticb ABc BGd ABxBG
Item - + - + SE effect effect   
Initial weight, kg 5.38 5.36 5.42 5.38 0.02 0.33 0.19 0.65 
Final weight, kg 102.67 108.01 109.30 110.51 2.43 0.20 0.08 0.41 
 ADG, kg 0.652 0.689 0.711 0.705 0.02 0.36 0.04 0.22 
 ADFI, kg 1.609 1.681 1.710 1.698 0.04 0.49 0.19 0.33 
 G:F 0.406 0.410 0.415 0.416 0.01 0.61 0.15 0.72 
Carcass         
 10th rib fat, cm 2.37 2.20 2.58 2.12 0.14 0.06 0.65 0.33 
 LMA, cm2 43.24 43.84 43.63 44.16 1.04 0.62 0.74 0.98 
 Fat-free lean, % 51.0 52.1 50.1 52.4 0.71 0.05 0.69 0.45 
 
a Least square means for 6 pens (4-6 pigs/pen) per treatment. 
b Provided 55 mg of carbadox per kg of completed feed in the nursery phase and 110 mg 









Effects of beta-glucan, antibiotic, and acidifier on  
growth performance of weanling pigs 
 
Introduction 
 Based on the results of the two previous experiments, the addition of beta-glucan 
improved growth and performance of pigs.  However, overall performance was better 
with the inclusion of antibiotics.  The addition of beta-glucan in the diet containing 
antibiotic numerically improved growth performance of weanling and growing-finishing 
pigs.    
Acidifiers (inorganic and organic acids) have been used in weanling pig diets not 
only as a feed preservative but more so as an antimicrobial alternative (Mathew, 2002).  
Acidifiers lower the pH of the gut and disrupt the cellular mechanisms of the pathogenic 
bacteria thus favoring the proliferation of beneficial bacteria.  Thus, this experiment was 
performed to determine the synergistic effect of combining beta-glucan and a commercial 
acidifier (Kem-Gest™) on growth and performance of pigs and comparing this effect 
with a standard antibiotic.  
 
Materials and Methods 
Two-hundred sixty pigs (average initial BW = 5.6 kg) were weaned at 
approximately 20 d of age.  Pigs were blocked by weight and randomly allotted to five 
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dietary treatments (8 pens/trt). The five dietary treatments consisted of 1) negative 
control (NC), 2) NC with 0.25% carbadox (AB), 3) NC with 0.20% beta-glucan, 4) NC 
with 0.20% acidifier, and 5) NC with 0.20% beta-glucan and 0.20% acidifier.  Carbadox 
(Mecadox®) was provided by Pfizer Animal Health (New York, NY), beta-glucan was 
provided by Dong-Ahm BT (Seoul, South Korea) and the acidifier was composed of 
inorganic (phosphoric acid) and organic acids (fumaric, lactic, and citric acid) and was 
provided by Kemin Industries (Des Moines, IA).  All diets were corn-soybean meal-
based (Table 5.1) and fed in meal form.  Pigs were fed in three dietary phases.  Phase 1 
diets (1.60% tLys) were fed from d 0 to d 14 and contained dried whey, lactose, fish 
meal, and soy protein concentrate.  Phase 2 diets (1.40% tLys) were fed from d 14 to d 28 
and contained dried whey, fish meal, and soy-protein concentrate.  Phase 3 diets (1.20% 
tLys) were fed from d 28 to 42 and were simple corn-soybean meal diet.  Pigs were 
housed (5-8 pigs/pen) in a temperature-controlled room and were allowed to have ad 
libitum access to feed and water throughout the experiment.  Pigs and feeders were 
weighed on d 0, 7, 14, 21, 28, 35, and 42 to determine average daily gain (ADG), average 
daily feed intake (ADFI), and feed efficiency (G:F ratio).   
Statistical Analysis – All data were analyzed as a randomized complete block design 
using analysis of variance procedures as described by Steel and Torrie (1997).  The 
model included the effects of replication, treatment, and replication x treatment (error).  
Treatment means were separated using Least Significant Difference.  The pen served as 




 In Phase 1, there were no differences (P > 0.10) in ADG, ADFI, and G:F of pigs 
fed carbadox, beta-glucan, or the negative control diet (Table 5.2).  However, the addition 
of acidifier tended to decrease (P < 0.08) ADG as compared to pigs fed beta-glucan.  
Moreover, pigs fed acidifier tended to consume less feed (P < 0.07) than pigs fed the 
negative control diet.  However, pigs fed acidifier had similar (P > 0.10) response as 
those pigs fed carbadox.  Pigs fed the combination of beta-glucan and acidifier had 
similar (P > 0.10) growth performance response as those pigs fed beta-glucan, carbadox, 
and the negative control diet.  However, the addition of beta-glucan in diets with acidifier 
tended to increase (P < 0.09) feed intake of pigs as compared to pigs fed the acidifier 
alone.  There were no differences (P > 0.10) in feed efficiency among the dietary 
treatments, although pigs fed beta-glucan numerically had the highest G:F (0.790). 
In Phase 2, pigs fed carbadox tended to have greater (P < 0.09) ADG than pigs fed 
the negative control diet, although the two dietary treatments had similar (P > 0.10) ADFI 
and G:F.  Addition of beta-glucan to the diet suppressed (P < 0.04) feed intake as 
compared to pigs fed either carbadox or the negative control diet, but it did not affect (P > 
0.10) ADG.  However, G:F of pigs fed beta-glucan tended to improve (P < 0.06) 
compared with pigs fed the negative control diet.  In addition, pigs fed beta-glucan had 
similar (P > 0.10) ADG, ADFI, and G:F to that of pigs fed the acidifier.  But the 
inclusion of acidifier reduced (P < 0.05) feed intake of pigs as compared to pigs fed 
carbadox and tended to lower (P < 0.09) ADFI of pigs as compared to pigs fed the 
negative control diet.  Combining both beta-glucan and acidifier in the diet resulted in 
similar (P > 0.10) ADG, ADFI, and G:F as compared to pigs fed carbadox, beta-glucan, 
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and acidifier.  However, G:F of pigs fed beta-glucan and acidifier combined was 
improved (P < 0.04) as compared with pigs fed the negative control diet. 
For Phases 1 and 2 combined, G:F of pigs fed carbadox was greater (P < 0.04) 
compared with pigs fed the negative control, although ADG and ADFI were similar (P > 
0.10).  Pigs fed beta-glucan had a similar (P > 0.10) response as those pigs fed carbadox.  
However, pigs fed beta-glucan had greater (P < 0.001) G:F than pigs fed the negative 
control diet.  Addition of acidifier decreased ADG (P < 0.06) and ADFI (P < 0.05) of 
pigs as compared to those pigs fed carbadox.  Furthermore, pigs fed acidifier had lower 
(P < 0.04) feed intake than pigs fed the negative control diet.  Pigs fed beta-glucan tended 
to have greater weight gain (P < 0.10) and better feed efficiency (P < 0.03) than pigs fed 
acidifier.  The combination of beta-glucan and acidifier resulted in similar (P > 0.10) 
ADG and ADFI of pigs as compared to the other dietary treatments.  Feed efficiency of 
pigs fed beta-glucan and acidifier combined tended to be greater (P < 0.06) than pigs fed 
the negative control diet, but tended to be lower (P < 0.09) than pigs fed beta-glucan.  
 In Phase 3, there were no differences (P > 0.10) in ADG and ADFI of pigs fed 
carbadox, beta-glucan or the negative control diet.  However, pigs fed carbadox had 
greater (P < 0.02) G:F than pigs fed the negative control diet.  The inclusion of acidifier 
in the diet tended to lower (P < 0.10) ADG of pigs as compared to those pigs fed either 
beta-glucan or carbadox.  However, ADFI and G:F of pigs fed acidifier were similar (P > 
0.10) as compared to pigs fed either beta-glucan, carbadox or the negative control diet.  
Pigs fed the combination of beta-glucan and acidifier had similar (P > 0.10) ADG and 
ADFI as compared to pigs fed either beta-glucan, carbadox, acidifier or the negative 
control diet.  But G:F was lower (P < 0.002) in pigs fed beta-glucan and acidifier 
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combined as compared to pigs fed carbadox.  Furthermore, pigs fed either beta-glucan or 
acidifier tended to have higher (P < 0.10) G:F than pigs fed the combination of beta-
glucan and acidifier.   
Overall, no differences (P > 0.10) in ADG and ADFI were observed in pigs fed 
either beta-glucan, carbadox or the negative control diet.  However, pigs fed either beta-
glucan or carbadox had greater (P < 0.02) G:F than pigs fed the negative control diet.  
The addition of acidifier lowered (P < 0.04) ADG of pigs as compared to pigs fed either 
beta-glucan or carbadox.  Moreover, pigs fed acidifier tended to consume less (P < 0.10) 
feed than pigs fed the negative control diet.  However, G:F of pigs fed acidifier was 
similar (P > 0.10) to pigs fed either beta-glucan, carbadox or the negative control diet.  
Pigs fed the combination of beta-glucan and acidifier had similar (P > 0.10) ADG and 
ADFI to pigs fed either beta-glucan, carbadox, acidifier or the negative control diet.  But 
the addition of beta-glucan to diets with acidifier decreased (P < 0.04) G:F of pigs as 
compared to pigs fed carbadox.  In addition, pigs fed the combination of beta-glucan and 
acidifier tended to have lower (P < 0.07) G:F than pigs fed beta-glucan.  The final weight 




 From previous experiments, it was shown that pigs fed beta-glucan had an 
intermediate growth performance response with pigs fed either carbadox or the negative 
control diet.  But in some phases, the effect of beta-glucan was greater than carbadox.  
Several alternatives claim to have antimicrobial activity, such as acidifiers, that have 
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comparable results with antibiotic.  Thus, this study compared the effect of combining 
beta-glucan and acidifier against antibiotic on growth performance of weanling pigs.  
 Partanen and Mroz (1999) reviewed several studies evaluating the effect of 
dietary organic acid addition to diets and they reported that for weaned piglets, fumaric 
and citric acid improved the average daily bodyweight gain and feed:gain ratio.  
Moreover, a study by De Rodas et al. (1995) evaluated the effect of diet acidification 
using a complex diet, in 20 to 26 d old pigs during a 6-wk study.  Phase 1 diets were 
composed of corn-soybean meal diet with 5% plasma protein, 1.5% spray-dried porcine 
blood meal, 5% fishmeal and 20% dried whey; Phase 2 diets were composed of corn-
soybean meal diet with 2% spray-dried porcine blood meal, 2.5% fishmeal and 5% dried 
whey; Phase 3 diets were simple corn-soybean meal diets.  They reported improvements 
in daily gains of pigs by 27% and 25% when pigs were fed with a 0.35% mixture of 
organic and inorganic acids, and 2% fumaric acid, respectively, as compared to pigs fed 
the control diet.  In addition, feed:gain ratio was also improved by 16% and 14% when 
pigs were fed the mixture of acidifiers and fumaric acid, respectively, as compared to 
pigs fed the control diet.  An experiment was conducted by Walsh et al. (2004b) 
evaluating the effect of acidifiers on growth performance of nursery pigs (18 d of age).  
They compared diets using treatments with a basal diet (no antibiotics, no acidifiers), 
basal diet with 50 ppm carbadox, basal diet with 0.40% organic acid blend, basal diet 
with 0.20% inorganic acid based blend, and basal diet with the combination of both 
organic and inorganic acids (0.60%).  They reported that the pigs fed carbadox had the 
highest ADG and G:F, although it was not significantly different from pigs fed either the 
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organic or inorganic acid blend.  But pigs fed diets with the combination of organic and 
inorganic acid blend consumed the least amount of feed.   
Similarly, in this experiment, the inclusion of acidifier resulted in the lowest 
growth performance among the dietary treatments.  Although the inclusion level of 
acidifier used in this experiment was not as high as compared to the study by Walsh et al. 
(2004b) (0.20% vs 0.60%), the levels and types of acids used, such as fumaric acid, could 
have change the palatability of the diet, thus, suppressing feed intake and depressing 
growth performance of pigs.  Moreover, the type of diets used could also have affected 
the growth performance response of feeding dietary organic acids (Partanen and Mroz, 
1999).  Burnell et al. (1988) reported in their study that addition of organic acid to corn-
soybean meal diet containing 15% dried whey resulted in greater weight gain and feed 
intake of weanling pigs than in simple corn-soybean meal diet, although no differences 
were observed in feed/gain response.  The study done by De Rodas et al. (1995) used 
only 20% and 5% dried whey in Phase 1 and Phase 2, respectively, while the study of 
Walsh et al. (2004b) used 25% and 15% dried whey in Phase 1 and Phase 2, respectively.  
In our study, 20% dried whey and 10% lactose were used in Phase 1 diet and 15% dried 
whey was used in Phase 2 diet.  However, pigs fed acidifier generally had lower growth 
performance response as compared to pigs fed the other dietary treatments.  These 
variable responses may be attributed to differences in dietary buffering capacity of 
ingredients (Bolduan et al., 1988; Partanen and Mroz, 1999), such as the source of 
proteins and minerals, which could affect the level of pH in the gut and efficiency of 
protein digestion (Blank et al., 1999), and eventually growth performance.  Makkink et 
al. (1994) reported in their study that pigs fed skim milk powder had higher protein 
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breakdown than pigs fed soybean protein concentrate, although no difference was seen on 
digesta pH.  This suggests that newly-weaned pigs lack the ability to digest vegetable 
protein sources compared to animal protein sources, such as milk by-products (Walsh et 
al, 2004a).   
 Growth performance of pigs fed carbadox was consistently higher than pigs fed 
acidifier.  These results were also similar with the results by Walsh et al. (2004b) where 
carbadox treated pigs had the highest ADG and better feed efficiency than pigs fed either 
the acid blends or the combination.  However, Virtanen et al. (2004) reported that a 
0.65% acid blend (formic acid, Na formate, phosphoric acid, lactic acid, citric acid in a 
diatomaceous earth carrier) improved ADG and feed efficiency of weanling pigs (25 d of 
age) by 19% and 4%, respectively, which was almost similar with pigs fed diets with 
0.40% avilamycin.   
In Phase 1 and Phases 1 and 2 combined, pigs fed beta-glucan had the greatest 
G:F.  The ADG and G:F of pigs fed the combination of beta-glucan and acidifier were 
lower than pigs fed either beta-glucan or carbadox in the same period.  However, pigs 
had better growth performance when beta-glucan was added to diets with acidifier as 
compared to pigs fed the acidifier alone.  Overall, pigs fed carbadox had the greatest 
ADG and G:F, followed by pigs fed beta-glucan.  The inconsistent results from previous 
studies and the present experiment, with regard to acidifier, may be due to the existing 
levels of performance where conditions were still favorable for the normal growth of pigs 




The addition of acidifiers was reported in other studies to improve growth 
performance of pigs, although it was not shown in this experiment.  Pigs fed acidifier had 
a reduction in feed intake, but this was alleviated when beta-glucan was added to the diet.  
Pigs fed beta-glucan had similar growth performance response as that of pigs fed 
carbadox.  However, pigs fed beta-glucan had greater growth performance response than 
pigs fed either acidifier or the combination of beta-glucan and acidifier. 
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Table 5.1. Composition of diets in Experiment 3 (as fed-basis)a.
Ingredient, % Phase 1  Phase 2  Phase 3 
Corn grain 30.01  46.72  57.49 
Soybean meal (48% CP) 15.46  20.19  35.13 
Whey, dried 20.00  15.00  0 
Lactose 10.00  0  0 
Fish menhaden meal 6.00  6.00  0 
Soy protein concentrate 12.00  6.00  0 
L-lysine HCL 0.10  0   
DL-methionine 0.12  0.05   
Soybean oil 4.00  4.00  4.00 
Dicalcium phosphate 0.45  0.21  1.04 
Limestone, ground 0.65  0.62  0.93 
Zinc oxide 0.28  0.28   
Copper sulfate     0.49 
Salt 0.50  0.50  0.50 
Trace mineral mixb 0.15  0.15  0.15 
Vitamin mixc 0.25  0.25  0.25 
Ethoxyquin 0.03  0.03  0.03 
Calculated Analysis:      
ME, kcal/kg 3,506  3,534  3,550 
Lysine, % 1.60  1.40  1.20 
Ca, % 0.95  0.85  0.75 
P, % 0.75  0.70  0.65 
Analyzed Composition:      
Crude Protein (as fed), % 24.49  22.95  20.54 
a Within each nursery phase, either 0.25% carbadoxd, 0.20% beta-glucan or 0.20% 
acidifiere was added to the basal diet to provide the five dietary treatments: 1) basal diet 
(BD), 2) BD + 0.25% carbadox, 3) BD + 0.20% beta-glucan, 4) BD + 0.20% acidifier, 
and 5) BD + 0.20% beta-glucan + 0.20% acidifier. 
b Supplied per kg of diet: 16.5 mg of Cu (copper sulfate); 165 mg of Fe (ferrous sulfate), 
0.30 mg of I (calcium iodate); 40 mg of Mn (manganese oxide); 0.30 mg of Se (sodium 
selenite); and 165 mg of Zn (zinc oxide). 
c Supplied per kg of diet: 11,013 IU of vitamin A; 1,652 IU of vitamin D3; 44 IU of 
vitamin E; 4.4 mg of vitamin K (menadione activity); 55 mg of niacin; 10 mg of 
riboflavin; 33 mg of pantothenic acid (D-calcium pantothenate); and 44 µg of vitamin 
B12.
d Provided 55 mg of carbadox per kg of complete feed. 




Table 5.2. Growth performance of weanling pigs (Exp. 3)a.
Treatmentb
NC AB 0.20% BG 0.20% AC 0.20% BG  SE 
Item         + 0.20% AC   
Number of pigs 52 52 52 52 52  
Initial weight, kg 5.58 5.59 5.58 5.58 5.56 0.02
Final weight, kg 16.18cd 16.90c 16.80c 15.74d 16.40cd 0.34
Phase 1       
 ADG, kg 0.170cd 0.158cd 0.172c 0.147d 0.169cd 0.01
ADFI, kg 0.225c 0.213cd 0.218cd 0.197d 0.224c 0.01
G:F 0.762 0.752 0.790 0.744 0.755 0.02
Phase 2       
 ADG, kg 0.320d 0.353c 0.331cd 0.320d 0.340cd 0.01
ADFI, kg 0.551c 0.557c 0.509d 0.516d 0.529cd 0.01
G:F 0.582d 0.633cd 0.646c 0.620cd 0.654c 0.02
Phases 1 & 2       
 ADG, kg 0.245cd 0.256c 0.252c 0.231d 0.247cd 0.01
ADFI, kg 0.388c 0.385c 0.363cd 0.353d 0.372cd 0.01
G:F 0.633e 0.666cd 0.691c 0.654de 0.664d 0.01
Phase 3       
 ADG, kg 0.267cd 0.297c 0.298c 0.251d 0.261cd 0.02
ADFI, kg 0.580 0.567 0.610 0.523 0.577 0.04
G:F 0.466de 0.525c 0.493cd 0.486cd 0.448e 0.02
Overall        
 ADG, kg 0.252cd 0.269c 0.267c 0.238d 0.251cd 0.01
ADFI, kg 0.452c 0.445cd 0.446cd 0.408d 0.439cd 0.02
G:F 0.563d 0.604c 0.600c 0.585cd 0.574d 0.01
a Least square means for 8 pens (5-8 pigs/pen) per treatment. 
b NC = negative control, AB = NC + carbadoxf, 0.20% BG = NC + 0.20% beta-
glucan, 0.20% AC = NC + 0.20% acidifierg, 0.20% BG + 0.20% AC = NC + 0.20% 
beta-glucan + 0.20% acidifier. 
c,d,e Within a row, means without a common superscript letter differ (P < 0.10). 
f Provided 55 mg of carbadox per kg of complete feed. 







Effects of beta-glucan, antibiotic, and probiotic on  
growth performance of weanling pigs 
 
Introduction 
 In the previous experiments, a synergistic effect of beta-glucan addition with the 
inclusion of an acidifier in the diet was not established in improving the growth and 
performance of weanling pigs.  However, a consistent response to beta-glucan was shown 
on growth performance, and in some phases, it was even greater than that obtained with 
carbadox inclusion in the first three experiments.  Thus, the possibility of further 
improving the performance of weanling pigs with the use of beta-glucan in combination 
with another antibiotic growth promotant alternative, such as probiotics, was 
investigated.  
 One of the probiotics or direct-fed microbial supplements is Lactobacillus 
acidophilus. A previous study performed by Lee et al. (2000), using a culture of 
Lactobacillus acidophilus L23, improved average daily gain of young pigs.  Because 
probiotics may modify the intestinal microflora, this experiment was performed to 
determine the effects of Lactobacillus acidophilus L23 in combination with beta-glucan 
on growth performance.   
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Materials and Methods 
A total of one-hundred pigs (average initial BW = 5.2 kg) was weaned at 
approximately 20 d of age.  Pigs were blocked by weight and randomly allotted to five 
dietary treatments (4 pens/trt).  The five dietary treatments consisted of: 1) negative 
control (NC), 2) NC with 0.25% carbadox (AB), 3) NC with 0.20% beta-glucan, 4) NC 
with probiotic, and 5) NC with 0.20% beta-glucan and probiotic.  Carbadox (Mecadox®) 
was provided by Pfizer Animal Health (New York, NY), beta-glucan was provided by 
Dong-Ahm BT (Seoul, South Korea) and the probiotic was a dried culture of 
Lactobacillus acidophilus L23 prepared by Culture Systems, Inc. (Granger, IN).  The 
probiotic culture was given to the pigs as a top-dress (1 x 108 cfu/pig) each morning in 
the nursery pen feeders.  All diets were corn-soybean meal-based and fed in meal form 
(Table 6.1).  Pigs were fed in three dietary phases.  Phase 1 diets (1.60% tLys) were fed 
from d 0 to d 14 and contained dried whey, lactose, fish meal, and soy protein 
concentrate.  Phase 2 diets (1.40% tLys) were fed from d 14 to d 28 and contained dried 
whey, fish meal, and soy-protein concentrate.  Phase 3 diets (1.20% tLys) were fed from 
d 28 to 42 and were a simple corn-soybean meal diet.  Pigs were housed (5 pigs/pen) in a 
temperature-controlled room and were allowed to have ad libitum access to feed and 
water throughout the experiment.  Pigs and feeders were weighed on d 0, 7, 14, 21, 28, 
35, and 42 to determine average daily gain (ADG), average daily feed intake (ADFI), and 
feed efficiency (G:F ratio).   
Blood collection and analysis - Blood was collected from three randomly selected pigs 
per pen.  Blood samples were taken via jugular venipuncture on d 0, 28 and 42 for the 
same three pigs using vacutainer tubes without anticoagulant for serum protein 
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determination.  The samples were centrifuged at approximately 1500 x g for 20 min and 
the serum was harvested and stored at -20oC.  The serum samples were later thawed for 
30 min at room temperature for serum protein quantification.  Serum samples were 
pooled within pen and IgA and IgG were quantified using the Pig ELISA Quantitation 
kits (Bethyl Laboratories, Inc., Montgomery, TX).  The serum proteins were then 
measured using the AD LD Analysis Software 1.6 and the AD 340 Absorbance Detector 
(Beckman Coulter, Inc., Fullerton, CA). 
Statistical Analysis – All growth performance and blood data were analyzed as a 
randomized complete block design using analysis of variance procedures as described by 
Steel and Torrie (1997).  The model included the effects of replication, treatment, and 
replication x treatment (error).  Treatment means were separated using Least Significant 
Difference.  The pen served as the experimental unit.  For the serum proteins, the effects 
of treatment, replication, and day were analyzed along with appropriate interactions using 
the PROC MIXED procedure of SAS. 
 
Results 
 In Phase 1, the ADG, ADFI, and G:F of pigs were similar (P > 0.10) between the 
negative control and carbadox diets (Table 6.2).  Pigs fed beta-glucan also had a response 
similar (P > 0.10) to those pigs fed either carbadox or the negative control diet.  The 
ADG and G:F of pigs fed diets top-dressed with probiotic did not differ (P > 0.10) as 
compared to those pigs fed beta-glucan, carbadox, or the negative control diet.  However, 
pigs fed probiotic tended to have greater (P < 0.06) ADFI than pigs fed the negative 
control diet.  Addition of probiotic to the diet with beta-glucan did not influence (P > 
0.10) the response of pigs.   
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In Phase 2, pigs fed carbadox had similar (P > 0.10) ADG, ADFI, and G:F as pigs 
fed the negative control diet.  The ADG, ADFI, and G:F also were similar (P > 0.10) 
among  pigs fed either beta-glucan, carbadox, and the negative control diet.  Pigs fed the 
diet top-dressed with probiotic had similar (P > 0.10) growth performance to those pigs 
fed either beta-glucan, carbadox, or the negative control diet.  The same trend was also 
noted for the addition of probiotic to the diet with beta-glucan where ADG, ADFI, and 
G:F were similar (P > 0.10) among pigs fed beta-glucan, carbadox, or probiotic.  
However, pigs fed beta-glucan top-dressed with probiotic tended to have greater (P < 
0.09) G:F than pigs fed the negative control diet.  
 In Phases 1 and 2 combined, pigs fed carbadox had similar (P > 0.10) ADG, 
ADFI, and G:F as those pigs fed the negative control diet.  In addition, growth 
performance of pigs was similar (P > 0.10) among pigs fed either beta-glucan, carbadox, 
or the negative control diet.  Addition of probiotic to the diet tended to improve (P < 
0.10) ADG of pigs as compared to those pigs fed the negative control diet.  Pigs fed beta-
glucan top-dressed with probiotic had similar (P > 0.10) ADG as compared to those pigs 
fed either the negative control, carbadox, beta-glucan, or probiotic.  However, ADFI of 
pigs tended to be reduced (P < 0.10) when beta-glucan was added to the diet top-dressed 
with probiotic. 
 In Phase 3, pigs fed carbadox had greater (P < 0.04) ADG and G:F than pigs fed 
the negative control diet, although ADFI of pigs was similar (P > 0.10) between pigs fed 
carbadox and the negative control diet.  The ADG and ADFI of pigs fed beta-glucan were 
similar (P > 0.10) to pigs fed either carbadox or the negative control.  However, G:F of 
pigs fed beta-glucan tended to be lower (P < 0.08) than pigs fed carbadox.  Moreover, 
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pigs fed beta-glucan had similar (P > 0.10) G:F compared with pigs fed the negative 
control diet.  Pigs fed probiotic tended to have lower (P < 0.09) ADG than pigs fed 
carbadox, although ADFI and G:F of pigs fed probiotic were similar (P > 0.10) to pigs 
fed either beta-glucan, carbadox or the negative control diet.  The ADG of pigs fed the 
combination of probiotic and beta-glucan was similar (P > 0.10) to those pigs fed either 
beta-glucan, carbadox, probiotic or the negative control diet.  However, pigs fed beta-
glucan top-dressed with probiotic had lower (P < 0.05) ADFI than pigs fed carbadox or 
the negative control diet.  The G:F was similar (P > 0.10) in pigs fed the combination of 
beta-glucan and probiotic as compared with those pigs fed carbadox.  However, beta-
glucan and probiotic combined improved (P < 0.03) G:F of pigs as compared to those 
pigs fed either beta-glucan, probiotic or the negative control diet.   
 Overall, pigs fed carbadox had greater (P < 0.03) ADG and G:F compared with 
pigs fed the negative control diet.  The ADG, ADFI, and G:F of pigs fed beta-glucan 
were similar (P > 0.10) to pigs fed either carbadox or the negative control diet.  Pigs fed 
the probiotic tended to have greater (P < 0.07) ADG than pigs fed the negative control 
diet, although they were similar (P > 0.10) to pigs fed either beta-glucan or carbadox.  
The ADFI and G:F of pigs fed probiotic also were similar (P > 0.10) to pigs fed either 
beta-glucan, carbadox or the negative control diet.  Pigs fed the combination of beta-
glucan and probiotic had similar (P > 0.10) ADG to pigs fed either beta-glucan, carbadox, 
probiotic or the negative control diet.  However, ADFI was decreased (P < 0.05) in pigs 
fed beta-glucan and probiotic combined as compared to pigs fed either probiotic or the 
negative control diet. Moreover, pigs fed the combination of beta-glucan and probiotic 
tended to have lower (P < 0.10) ADFI than pigs fed either carbadox or beta-glucan.  The 
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G:F of pigs fed the combination of beta-glucan and probiotic was similar (P > 0.10) to 
pigs fed carbadox, although it was greater (P < 0.05) than pigs fed either beta-glucan, 
probiotic, or the negative control diet.  The final weight of pigs tended to be higher (P < 
0.09) in pigs fed carbadox than those pigs fed the negative control, although it was 
similar (P > 0.10) to pigs fed either beta-glucan, probiotic or the combination of beta-
glucan and probiotic. 
 A day effect was observed (P < 0.01) on immunoglobulin levels (Table 6.3) but 
there was no day by treatment effect (P > 0.10).  For the serum proteins, IgA levels at d 0 
was similar (P > 0.10) in pigs fed either the negative control diet, carbadox, beta-glucan, 
or beta-glucan and probiotic combined.  However, pigs fed the probiotic tended to have 
higher (P < 0.07) initial IgA levels than pigs fed beta-glucan.  On d 28 and 42, there were 
no differences (P > 0.10) in IgA levels of pigs fed the negative control diet, carbadox, 
beta-glucan or probiotic.  However, pigs fed the combination of beta-glucan and probiotic 
tended to have increased (P < 0.10) IgA levels compared with pigs fed beta-glucan. 
 Initially, at d 0, IgG levels were similar (P > 0.10) in pigs fed either the negative 
control diet, carbadox, probiotic or the combination of beta-glucan and probiotic.  
However, pigs fed beta-glucan tended to have lower (P < 0.10) initial IgG levels than 
pigs fed either carbadox or the combination of beta-glucan and probiotic.  On d 28, IgG 
levels were similar in pigs fed either the negative control, carbadox, probiotic, or beta-
glucan and probiotic combined.  Still, beta-glucan addition to the diet tended to have 
reduced (P < 0.06) IgG levels than inclusion of probiotic.  On d 42, pigs fed carbadox had 
similar (P > 0.10) IgG levels as those pigs fed beta-glucan.  In the same period, IgG 
levels were increased (P < 0.01) with probiotic addition to the diet, as compared to the 
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negative control diet.  Moreover, pigs fed either the negative control diet or beta-glucan 
and probiotic combined tended to have increased (P < 0.10) IgG levels as compared to 
pigs fed the negative control diet. 
 
Discussion 
 Weanling pigs experience stress from their diets and new environment which 
could lead to a depression in growth performance.  These stresses leading to the reduction 
in performance may be alleviated in young pigs with supplementation of probiotics.  This 
was evidenced in this experiment, where pigs fed the probiotic culture, Lactobacillus 
acidophilus L23, had greater ADG and G:F than pigs fed the negative control diet.  A 
study by Lee et al. (2001) used the same probiotic culture, with a different strain, 
preparation, and administration (orally administered with milk), in weanling pigs fed 
corn-soybean meal diet with low lactose whey protein concentrate (10% in Phase 1, none 
in Phase 2) and 3% soybean protein concentrate (both in Phase 1 and Phase 2).  In their 
study, pigs that received a low or high dose of L. acidophilus L23 (3 x 108
lactobacilli/day vs 3 x 109 lactobacilli/day) had higher ADG and better feed:gain ratio 
than pigs in the control group as a result of a possible increase in starch digestibility.  But 
it should be noted that the probiotic culture used by Lee et al. (2001) was prepared using 
a different strain, method, and purpose, thus, further investigation could be done to 
determine the effect of that probiotic culture on growth performance of weanling pigs.  
Pollmann et al. (1980) performed two experiments (4-wk study) to evaluate the 
effects of adding a probiotic product of lactobacillus origin to the diet of weanling pigs.  
In Exp. 1, weanling pigs (28 d old) were fed a complex corn-soybean meal diet with 10% 
dried whey and growth performance was compared using a commercial probiotic, 
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Probios (L. acidophilus), different kinds of antibiotics (ASP-250, tylosin or lincomycin) 
and a control diet.  The authors reported that probiotic supplementation improved ADG 
and feed conversion ratio of pigs by 4.5% and 7.2%, respectively, as compared to non-
supplementation.  In Exp. 2, the probiotic was compared to lactic acid, virginiamycin, 
and another commercial probiotic from Streptococcus faecium (Feed-Mate 68).  Pigs 
(average initial BW = 7 kg) were fed a less complex corn-soybean meal diet without 
dried whey.  Results were more pronounced this time, with improvements in ADG by 
9.7% and feed conversion ratio by 21.4%, as compared to pigs fed the control diet.   
However, a study by Harper and Estienne (2002) reported that a probiotic culture 
from Bacillus licheniformis and B. subtilis (BioMate-2B, Chris Hansen Biosystems) fed 
to nursery pigs resulted in lower ADG, ADFI, and poorer feed conversion ratio.  In their 
5-wk study, pigs were fed a complex corn-soybean meal diet with dried whey and were 
compared to pigs fed either the control or carbadox.  These authors reported that 
inclusion of the probiotic culture reduced ADG and ADFI of pigs by -5.2% and -2.6%, 
respectively, and increased feed conversion ratio by 2.5%, when compared to pigs fed the 
control diet.  However, ADG and ADFI of pigs fed carbadox were improved by 7.9% and 
5.0%, respectively, and feed conversion ratio was decreased by 3.1%.   
 In the present study, probiotic addition to the diet of pigs resulted in greater feed 
consumption than pigs fed either carbadox or the negative control diet, which resulted in 
comparable improvements in ADG and feed efficiency.  However, ADG and G:F of pigs 
fed probiotic were improved by 6.14% and 7.51%, respectively, unlike in other probiotic 
studies, where growth performance was reduced.  This was anticipated because probiotics 
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promote the colonization of beneficial microorganisms colonization in the gut, thus, 
inhibiting the growth of pathogenic bacteria (Abe et al., 1995).      
As in the previous experiments, beta-glucan supplementation to the diet improved 
growth performance of pigs. The ADG and G:F of pigs were improved by 5.42% and 
7.51%, respectively, with addition of beta-glucan in the diet as compared to non-addition.  
Although no synergistic effects were observed in combining beta-glucan with acidifiers 
in Experiment 3, addition of probiotic to the diet with beta-glucan in this experiment 
resulted in higher growth performance of pigs compared with pigs fed the diet containing 
carbadox.  Moreover, the greatest overall G:F was observed in pigs fed the combination 
of beta-glucan and probiotic (0.593).  The ADG and G:F of pigs fed beta-glucan and 
probiotic combined were increased by 5.05% and 17.19%, respectively, as compared to 
pigs fed the negative control diet.       
 Serum protein levels generally indicate the immune status of the animals, where 
higher numbers indicate greater immune activation.  Immunoglobulins or antibodies have 
binding sites for both antigens and pathogens and these promote interaction with the 
immune system that leads to the destruction of pathogens (Yaqoob and Calder, 2003).  
Aside from this neutralization process, immunoglobulins also activate complement 
plasma proteins that can also destroy pathogens (Yaqoob and Calder, 2003).  White et al. 
(2002) stated that an antigenic response from fungi, e.g. Saccharomyces cerevisiae, not
only activates the B-lymphocytes that produce the immunoglobulins, but it also activates 
the complement system, thus, increasing the response of neutrophils and activation of 
macrophages.  In their study, the authors reported that weanling pigs fed 3% brewers 
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yeast had higher serum IgG levels as compared to a basal or carbadox treated diet, but 
serum IgA levels were not affected by yeast or carbadox treatment.  
In the present experiment, pigs fed beta-glucan had the lowest IgA and IgG levels 
for the whole duration of the experiment.  The IgA levels of pigs for all dietary 
treatments were increased in each period, with the greatest percentage increase in pigs fed 
beta-glucan and probiotic combined at 41% from d 0 to 28.  From d 28 to 42, pigs fed the 
negative control diet had the greatest percentage increase in IgA levels at 68%.  Overall 
(d 0 to d 42), pigs fed the combination of beta-glucan and probiotic had the highest 
percentage increase in IgA levels at 707%, whereas pigs fed carbadox had the lowest 
(360%).  On the other hand, IgG levels for all treatments were decreased on d 28, where 
pigs fed carbadox had the greatest reduction at -47%, and pigs fed the probiotic had the 
least reduction (-8%).  The levels of IgG in all treatments were increased again on d 42, 
and pigs fed carbadox had the greatest percentage increase (41%).  From d 0 to d 42, pigs 
fed the combination of beta-glucan and probiotic had the greatest reduction in IgG levels 
at -27%, whereas pigs fed the negative control had the greatest increase at 10%. 
 Based on the study of White et al. (2002), it was expected that beta-glucan, which 
originated from yeast cell wall, would increase immunoglobulin levels of pigs, 
particularly that of IgG.  But in the present experiment, beta-glucan only had an 
intermediate response compared to other dietary treatments.  The low response of beta-
glucan in this experiment could have been due to a lower concentration of beta-glucan 
used as compared to the study by White et al. (0.20% vs 3%), which might not be enough 
to stimulate immunoglobulin production.  On the other hand, pigs fed carbadox had the 
lowest percentage increase in IgA and IgG levels, which was similar to the study by 
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White et al. (2002).  One of the mechanisms of antibiotics is the suppression of pathogens 
(Gaskins et al., 2002) and the low levels of immunoglobulins might be a result of lower 
immune system activation due to carbadox addition in the diet.  
 
Conclusions 
The addition of probiotic to diets with or without beta-glucan improved growth 
performance of pigs.  Pigs fed beta-glucan had similar growth performance response as 
that of probiotic addition in the diet.  The addition of either beta-glucan or carbadox 
influenced serum protein levels.  The combination of beta-glucan and probiotic in diets of 
pigs further improved growth response.  By altering the intestinal microflora and/or by 
stimulating the immune system, these alternatives hold a promise in replacing antibiotic 
growth promotants, which could result in the decrease of antibiotic usage in diets of pigs.  
However, this synergistic effect needs further confirmation in future studies. 
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Table 6.1. Composition of diets in Experiment 4 (as fed-basis)a.
Ingredient, % Phase 1  Phase 2  Phase 3 
Corn grain 30.01  46.72  57.49 
Soybean meal (48% CP) 15.46  20.19  35.13 
Whey, dried 20.00  15.00  0 
Lactose 10.00  0  0 
Fish menhaden meal 6.00  6.00  0 
Soy protein concentrate 12.00  6.00  0 
L-lysine HCL 0.10  0   
DL-methionine 0.12  0.05   
Soybean oil 4.00  4.00  4.00 
Dicalcium phosphate 0.45  0.21  1.04 
Limestone, ground 0.65  0.62  0.93 
Zinc oxide 0.28  0.28   
Copper sulfate     0.49 
Salt 0.50  0.50  0.50 
Trace mineral mixb 0.15  0.15  0.15 
Vitamin mixc 0.25  0.25  0.25 
Ethoxyquin 0.03  0.03  0.03 
Calculated Analysis:      
ME, kcal/kg 3,506  3,534  3,550 
Lysine, % 1.60  1.40  1.20 
Ca, % 0.95  0.85  0.75 
P, % 0.75  0.70  0.65 
Analyzed Composition:      
Crude Protein (as fed), % 24.66  22.83  20.79 
a Within each nursery phase, either 0.25% carbadoxd, 0.20% beta-glucan or 
probiotice was added to the basal diet to provide the five dietary treatments: 1) 
basal diet ((BD), 2) BD + 0.25% carbadox, 3) BD + 0.20% beta-glucan, 4) BD + 
probiotic, and 5) BD + 0.20% beta-glucan + probiotic. 
b Supplied per kg of diet: 16.5 mg of Cu (copper sulfate); 165 mg of Fe (ferrous 
sulfate), 0.30 mg of I (calcium iodate); 40 mg of Mn (manganese oxide); 0.30 mg 
of Se (sodium selenite); and 165 mg of Zn (zinc oxide). 
c Supplied per kg of diet: 11,013 IU of vitamin A; 1,652 IU of vitamin D3; 44 IU 
of vitamin E; 4.4 mg of vitamin K (menadione activity); 55 mg of niacin; 10 mg 
of riboflavin; 33 mg of pantothenic acid (D-calcium pantothenate); and 44 µg of
vitamin B12.
d Provided 55 mg of carbadox per kg of complete feed. 
e Added Lactobacillus acidophilus L23 top-dressed in pen-feeders. 
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Table 6.2. Growth performance of weanling pigs (Exp. 4)a.
Treatmentb
Item NC AB 0.20% BG NC + PB 0.20% BG + PB SE 
Number of pigs 20 20 20 20 20  
Initial weight, kg 5.23 5.23 5.25 5.24 5.24 0.04
Final weight, kg 17.05d 17.93c 17.50cd 17.62cd 17.47cd 0.33
Phase 1       
 ADG, kg 0.163 0.176 0.178 0.188 0.187 0.01
ADFI, kg 0.268d 0.294cd 0.278cd 0.302c 0.293cd 0.01
G:F 0.608 0.598 0.638 0.624 0.646 0.03
Phase 2       
 ADG, kg 0.389 0.405 0.401 0.403 0.376 0.02
ADFI, kg 0.648 0.654 0.630 0.656 0.591 0.03
G:F 0.598d 0.623cd 0.636cd 0.616cd 0.642c 0.02
Phases 1 & 2       
 ADG, kg 0.272d 0.288cd 0.290cd 0.294c 0.282cd 0.01
ADFI, kg 0.451cd 0.470cd 0.454cd 0.476c 0.442d 0.01
G:F 0.601 0.615 0.637 0.618 0.644 0.02
Phase 3       
 ADG, kg 0.285d 0.321c 0.296cd 0.292d 0.310cd 0.01
ADFI, kg 0.740c 0.659cd 0.705c 0.676cd 0.600d 0.03
G:F 0.386e 0.490cd 0.422e 0.432de 0.521c 0.02
Overall        
 ADG, kg 0.277d 0.299c 0.292cd 0.294c 0.291cd 0.01
ADFI, kg 0.546c 0.532c 0.538c 0.542c 0.495d 0.01
G:F 0.506e 0.563cd 0.544de 0.544de 0.593c 0.02
a Least square means for 4 pens (5 pigs/pen) per treatment. 
b NC = negative control, AB = NC + carbadoxf, 0.20% BG = NC + 0.20% beta-glucan, 
NC + PB = NC + 0.20% probioticg, 0.20% BG + PB = NC + 0.20% beta-glucan + 
probiotic. 
c,d,e Within a row, means without a common superscript letter differ (P < 0.10). 
f Provided 55 mg of carbadox per kg of complete feed. 
g Added Lactobacillus acidophilus L23 top-dressed in pen-feeders. 
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Table 6.3. Serum immune proteins (Exp. 4)a.
Treatmentbc 
Item NC AB 0.20% BG NC + PB 
0.20% 
BG + PB SE 
Number of pigs 12 12 12 12 12  
IgA, mg/100 mL       
 Day 0 8.79de 9.88de 7.50e 10.51d 8.44de 1.03 
 Day 28 35.01de 33.43de 30.55e 35.77de 41.32d 4.23 
 Day 42 58.87de 45.43de 43.37e 55.48de 68.14d 9.47 
 
IgG, mg/100 mL       
 Day 0 440.6de 623.1d 416.9e 525.9de 636.8d 71.44 
 Day 28 346.2de 329.6de 283.2e 482.2d 388.9de 65.47 
 Day 42 485.3d 463.3de 353.9e 544.1d 463.9d 43.29 
a Least square means for 4 pens (3 pigs/pen) per treatment. 
b NC = negative control, AB = NC + carbadoxf, 0.20% BG = NC + 0.20% beta-glucan, 
NC + PB = NC + 0.20% probioticg, 0.20% BG + PB = NC + 0.20% beta-glucan + 
probiotic. 
c Day effect (P < 0.01), Day*Treatment (P > 0.10). 
d,e Within a row, means without a common superscript letter differ (P < 0.10). 
f Provided 55 mg of carbadox per kg of complete feed. 









From the previous four experiments that were conducted, 26 replicates were 
summarized to evaluate the effects of beta-glucan and antibiotic on growth and 
performance of weanling pigs.  Three dietary treatments were considered: 1) negative 
control (NC), 2) NC + 0.20% carbadox (AB), and 3) NC + 0.20% beta-glucan (BG).  In 
each treatment, a total of 26 replications was used to evaluate ADG, ADFI, and G:F 
through the end of Phase 2 (28 days).  Data were analyzed as a randomized complete 
block design using analysis of variance procedures as described by Steel and Torrie 
(1997).  The model included the effects of replication, treatment, and experiment x 
treatment.  Replication-within-experiment was considered a random effect.  Treatment 




 An experiment effect (P < 0.01) was observed in all growth parameters measured 
but there was no experiment and treatment interaction noted (P > 0.10).  In Phase 1, there 
were no differences (P > 0.10) in growth performance among the dietary treatments, 
although numerically, pigs fed beta-glucan had the greatest ADG and G:F (0.169 kg and 
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0.681, respectively) (Table 7.1).  In Phase 2, ADG of pigs was greater (P < 0.01) with 
carbadox inclusion in the diet as compared to pigs fed the negative control diet.  The 
ADG of pigs fed beta-glucan was intermediate to that of pigs fed either carbadox or the 
negative control diet.  Carbadox addition to the diet tended to increase (P < 0.10) feed 
intake of pigs as compared to beta-glucan and the negative control diet.  Pigs fed either 
carbadox or beta-glucan had greater (P < 0.02) G:F than pigs fed the negative control 
diet.  In Phases 1 and 2 combined, pigs fed carbadox had greater (P < 0.01) ADG than 
pigs fed the negative control diet.  The inclusion of beta-glucan in the diet tended to 
improve (P < 0.07) ADG of pigs as compared to those pigs fed the negative control diet.  
Pigs fed carbadox had greater (P < 0.04) ADFI than pigs fed the negative control diet.  
The G:F of pigs was increased (P < 0.04) when pigs were fed either carbadox or beta-
glucan as compared to those pigs fed the negative control diet.  Numerically, pigs fed 
beta-glucan had greater G:F than pigs fed carbadox. 
 
Discussion 
In all phases, inclusion of carbadox resulted in greater ADG, ADFI, and G:F of 
pigs as compared to pigs fed the negative control diet.  These growth performance 
responses agree with a report by Cromwell (2001), where addition of antibiotic in starter 
diets resulted in improvements in growth rate and feed efficiency (16.4% and 6.9%, 
respectively).  However, the response to antibiotic addition in this study improved ADG 
and G:F by 7.06% and 3.39%, respectively, when compared to the negative control diet 
(Figure 7.1).  This lower growth response could be attributed to the existing disease level 
at the experiment station.  Cromwell (2001) stated that antibiotics prevent proliferation of 
pathogenic microorganisms, which cause specific and non-specific diseases that could 
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hinder growth performance.  However, Cromwell (2001) also stated that the effect of 
antibiotic is less pronounced in a “clean”, more hygienic environment than in “dirty”, 
unsanitary environment.  The nursery rooms that were used in this study were properly 
cleaned and disinfected, which could have eliminated some growth-depressing 
pathogens.  Moreover, the response to antibiotics in research facilities is usually lower 
than that in commercial farm settings due to the same reasons listed above (Cromwell, 
2001). 
Beta-glucan supplementation consistently improved ADG and G:F of pigs, as 
compared to pigs fed the negative control diet.  The response of beta-glucan was 
improvements in ADG by 4.31% and G:F by 4.01% (Figure 7.2), when compared to pigs 
fed the negative control diet.  Other alternatives, such as MOS, had similar improvements 
in growth performance.  Pettigrew (2000) stated in his review that supplementation of 
MOS improved ADG and feed efficiency by 4.4% and 1.47%, respectively, when 
compared to diets without MOS.  Although the growth performance response of beta-
glucan was smaller than that of antibiotic, it is still clear that beta-glucan improves 
growth performance.  The overall mean percentage response of pigs in ADG to beta-
glucan addition was approximately half of the response obtained with carbadox inclusion 
in the diet.  For G:F of pigs, it was slightly improved with beta-glucan supplementation 
as compared to carbadox addition in the diet.  This summary was consistent with 
previous experiments, where beta-glucan had an intermediate response on growth 
performance between carbadox or the negative control diet.  
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Table 7.1. Growth performance of weanling pigs from Exp. 1 to Exp. 4 (26 reps)ab.
Treatmentc
Item NC AB BG SE 
Number of pigs 151 151 151  
Initial weight, kg 5.50 5.50 5.51 0.01 
Final weight, kgf 18.14e 18.80d 18.48de 0.17 
Phase 1     
 ADG, kg 0.163 0.167 0.169 0.01 
 ADFI, kg 0.247 0.253 0.249 0.01 
 G:F 0.666 0.667 0.681 0.01 
Phase 2     
 ADG, kg 0.353e 0.384d 0.367de 0.01 
 ADFI, kg 0.557 0.579 0.554 0.01 
 G:F 0.635e 0.664d 0.662d 0.01 
Phases 1 & 2     
 ADG, kg 0.257e 0.275d 0.268de 0.01 
 ADFI, kg 0.399e 0.414d 0.400de 0.01 
 G:F 0.645e 0.665d 0.671d 0.01 
a Least square means for 26 pens (5-8 pigs/pen) per treatment. 
b Experiment effect (P < 0.01), Experiment*Treatment (P > 0.10). 
c NC = negative control, AB = NC + carbadoxg, BG = NC + 0.20% beta-glucan. 
d,e Within a row, means without a common superscript letter differ (P < 0.10). 
f Final weight of pigs at the end of Phase 3.  




















Figure 7.1. Percentage improvement in ADG due to carbadox or beta-glucan 

















Figure 7.2. Percentage improvement in G:F due to carbadox or beta-glucan 






Based on the results of the four experiments, addition of beta-glucan in the diet 
improved the growth performance response of weanling pigs.  Pigs fed beta-glucan 
appeared to have a growth performance response that was intermediate to that of 
carbadox or feeding the negative control diet.  The inclusion of acidifier and probiotic 
resulted in variable responses on growth performance when compared to pigs fed beta-
glucan or carbadox.  No interaction was observed in combining beta-glucan and 
carbadox.  However, slight improvements in ADG, ADFI, and G:F were noted when 
beta-glucan was combined with either acidifier or probiotic.  The immune response of 
pigs generally was not affected with supplementation of either beta-glucan, carbadox, 
acidifier, or probiotic.  These results suggest that beta-glucan can be used as an 
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Appendix Table 1. Means for average daily gain, average daily feed intake, and  
gain:feed for Phase 1 and Phase 2 - Experiment 1. 
 Phase 1  Phase 2 
Trt Rep ADG (kg) ADFI (kg) G:F  ADG (kg) ADFI (kg) G:F 
1 1 0.144 0.262 0.550 0.355 0.548 0.649
2 1 0.155 0.304 0.510 0.431 0.612 0.704
3 1 0.194 0.300 0.646 0.445 0.681 0.654
4 1 0.160 0.261 0.615 0.398 0.680 0.586
1 2 0.150 0.228 0.658 0.370 0.531 0.696
2 2 0.118 0.183 0.641 0.342 0.498 0.687
3 2 0.141 0.219 0.644 0.330 0.469 0.702
4 2 0.143 0.245 0.585 0.298 0.444 0.672
1 3 0.166 0.291 0.572 0.257 0.411 0.625
2 3 0.130 0.320 0.408 0.296 0.455 0.651
3 3 0.116 0.292 0.398 0.303 0.450 0.673
4 3 0.080 0.221 0.364 0.347 0.428 0.810
1 4 0.135 0.307 0.439 0.236 0.383 0.617
2 4 0.168 0.240 0.698 0.328 0.492 0.667
3 4 0.106 0.239 0.442 0.260 0.395 0.659
4 4 0.122 0.245 0.499 0.213 0.313 0.681
1 5 0.207 0.302 0.687 0.408 0.565 0.723
2 5 0.256 0.323 0.793 0.537 0.687 0.781
3 5 0.296 0.370 0.800 0.504 0.666 0.757
4 5 0.198 0.294 0.674 0.417 0.559 0.746
1 6 0.215 0.264 0.813 0.443 0.625 0.709
2 6 0.213 0.286 0.743 0.400 0.602 0.664
3 6 0.209 0.294 0.710 0.434 0.611 0.710
4 6 0.198 0.243 0.813 0.445 0.646 0.689
1 7 0.179 0.253 0.707 0.415 0.542 0.766
2 7 0.217 0.306 0.709 0.415 0.579 0.716
3 7 0.183 0.271 0.674 0.379 0.612 0.619
4 7 0.171 0.216 0.792 0.372 0.546 0.681
1 8 0.182 0.291 0.625 0.392 0.556 0.705
2 8 0.162 0.226 0.715 0.387 0.522 0.741
3 8 0.159 0.238 0.668 0.346 0.517 0.670
4 8 0.128 0.202 0.633 0.365 0.513 0.710
Trt 1: negative control diet (0.40% cornstarch). 
Trt 2: diet + 0.25% carbadox + 0.15% cornstarch. 
Trt 3: diet + 0.20% beta-glucan + 0.20% cornstarch.   
Trt 4: diet + 0.40% beta-glucan. 
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Appendix Table 2. Analysis of variance for average daily gain, average daily feed 
intake, and gain:feed for Phase 1 and Phase 2 - Experiment 1. 
 Mean Squares 
Phase 1  Phase 2 
Source d.f. ADG ADFI G:F  ADG ADFI G:F 
Total 31        
Error 21 0.00063 0.00089 0.00546 0.00139 0.00204 0.00215
Repetition 7 0.00652 0.00383 0.05308 0.01902 0.03227 0.00401
Treatment 3 0.00129 0.00241 0.00158 0.00211 0.00331 0.00073
Coefficient of         
Variation, %   14.81 11.16 11.69  10.04 8.43 6.70 
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Appendix Table 3. Means for average daily gain, average daily feed intake, and  
gain:feed for Phases 1 & 2 combined and Phase 3 - Experiment 1. 
 Phases 1 & 2  Phase 3 
Trt Rep ADG (kg) ADFI (kg) G:F  ADG (kg) ADFI (kg) G:F 
1 1 0.250 0.405 0.617 0.510 0.804 0.634
2 1 0.293 0.458 0.640 0.545 0.793 0.688
3 1 0.320 0.491 0.651 0.567 0.845 0.670
4 1 0.279 0.470 0.594 0.444 0.861 0.516
1 2 0.260 0.380 0.685 0.546 0.823 0.664
2 2 0.230 0.341 0.675 0.536 0.754 0.711
3 2 0.236 0.345 0.684 0.451 0.704 0.641
4 2 0.217 0.339 0.639 0.483 0.800 0.604
1 3 0.212 0.339 0.625 0.394 0.659 0.598
2 3 0.213 0.350 0.610 0.481 0.745 0.646
3 3 0.209 0.330 0.635 0.399 0.649 0.615
4 3 0.214 0.296 0.722 0.434 0.679 0.639
1 4 0.183 0.316 0.578 0.375 0.637 0.589
2 4 0.248 0.373 0.664 0.460 0.758 0.607
3 4 0.183 0.298 0.613 0.435 0.670 0.650
4 4 0.168 0.264 0.634 0.371 0.578 0.642
1 5 0.308 0.434 0.710 0.472 0.838 0.564
2 5 0.396 0.505 0.784 0.360 0.881 0.408
3 5 0.400 0.518 0.772 0.511 0.911 0.561
4 5 0.308 0.427 0.721 0.438 0.800 0.548
1 6 0.329 0.444 0.740 0.498 0.939 0.530
2 6 0.306 0.444 0.689 0.429 0.713 0.601
3 6 0.321 0.453 0.710 0.466 0.829 0.562
4 6 0.321 0.445 0.722 0.466 0.829 0.562
1 7 0.297 0.398 0.748 0.379 0.818 0.464
2 7 0.316 0.442 0.714 0.408 0.774 0.527
3 7 0.281 0.442 0.635 0.422 0.891 0.474
4 7 0.271 0.381 0.713 0.481 0.820 0.587
1 8 0.287 0.424 0.677 0.465 0.799 0.582
2 8 0.274 0.374 0.733 0.475 0.757 0.627
3 8 0.253 0.377 0.670 0.398 0.758 0.525
4 8 0.235 0.343 0.685 0.481 0.806 0.597
Trt 1: negative control diet (0.40% cornstarch). 
Trt 2: diet + 0.25% carbadox + 0.15% cornstarch. 
Trt 3: diet + 0.20% beta-glucan + 0.20% cornstarch.   
Trt 4: diet + 0.40% beta-glucan. 
 
100
Appendix Table 4. Analysis of variance for average daily gain, average daily feed 
intake, and gain:feed for Phases 1 & 2 combined and Phase 3 - Experiment 1. 
 Mean Squares 
Phases 1 & 2  Phase 3 
Source d.f. ADG ADFI G:F  ADG ADFI G:F 
Total 31        
Error 21 0.00065 0.00086 0.00134 0.00236 0.00352 0.00286
Repetition 7 0.01151 0.01479 0.00783 0.00584 0.02066 0.01104
Treatment 3 0.00158 0.00264 0.00005 0.00019 0.00061 0.00078
Coefficient of         
Variation, %   9.50 7.42 5.40  10.66 7.61 9.09 
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Appendix Table 5. Means for average daily gain, average daily feed intake, 
and gain:feed for the entire 42-d period - Experiment 1. 
 Overall 
Trt Rep ADG (kg) ADFI (kg)  GF 
1 1 0.336 0.538 0.625
2 1 0.377 0.569 0.663
3 1 0.396 0.601 0.659
4 1 0.334 0.600 0.557
1 2 0.355 0.528 0.674
2 2 0.331 0.478 0.693
3 2 0.307 0.464 0.662
4 2 0.296 0.476 0.621
1 3 0.268 0.447 0.601
2 3 0.302 0.507 0.597
3 3 0.272 0.464 0.588
4 3 0.287 0.443 0.648
1 4 0.239 0.429 0.557
2 4 0.319 0.497 0.642
3 4 0.267 0.434 0.614
4 4 0.235 0.378 0.622
1 5 0.363 0.568 0.638
2 5 0.384 0.630 0.610
3 5 0.437 0.649 0.673
4 5 0.351 0.551 0.638
1 6 0.385 0.609 0.632
2 6 0.347 0.533 0.650
3 6 0.370 0.578 0.639
4 6 0.370 0.573 0.645
1 7 0.325 0.538 0.604
2 7 0.346 0.553 0.627
3 7 0.322 0.574 0.562
4 7 0.341 0.528 0.647
1 8 0.346 0.549 0.631
2 8 0.341 0.502 0.681
3 8 0.296 0.489 0.604
4 8 0.312 0.488 0.640
Trt 1: negative control diet (0.40% cornstarch). 
Trt 2: diet + 0.25% carbadox + 0.15% cornstarch. 
Trt 3: diet + 0.20% beta-glucan + 0.20% cornstarch.   
Trt 4: diet + 0.40% beta-glucan. 
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Appendix Table 6. Analysis of variance for average daily gain, average daily 
feed intake, and gain:feed for the entire 42-d period – Experiment 1. 
Mean Squares 
Overall 
Source d.f. ADG ADFI G:F 
Total 31    
Error 21 0.00067 0.00114 0.00107 
Repetition 7 0.00680 0.01410 0.00154 
Treatment 3 0.00107 0.00141 0.00096 
Coefficient of     
Variation, %   7.86 6.44 5.20 
103
Appendix Table 7. Means for average daily gain, average daily feed intake, and  
gain:feed for Nursery Phase 1 and Phase 2 - Experiment 2. 
 Phase 1  Phase 2 
Trt Rep ADG (kg) ADFI (kg) G:F  ADG (kg) ADFI (kg) G:F 
1 1 0.157 0.222 0.707 0.296 0.448 0.661
2 1 0.148 0.216 0.686 0.346 0.515 0.671
3 1 0.201 0.254 0.791 0.297 0.459 0.649
4 1 0.192 0.239 0.805 0.358 0.510 0.702
1 2 0.153 0.227 0.673 0.287 0.447 0.643
2 2 0.178 0.272 0.655 0.330 0.512 0.644
3 2 0.132 0.191 0.689 0.324 0.452 0.718
4 2 0.187 0.253 0.740 0.389 0.518 0.752
1 3 0.163 0.227 0.719 0.283 0.415 0.683
2 3 0.168 0.230 0.729 0.272 0.401 0.680
3 3 0.154 0.200 0.771 0.314 0.429 0.730
4 3 0.153 0.215 0.709 0.326 0.438 0.746
1 4 0.138 0.207 0.670 0.457 0.630 0.726
2 4 0.149 0.242 0.617 0.520 0.701 0.741
3 4 0.146 0.221 0.660 0.449 0.649 0.693
4 4 0.186 0.241 0.772 0.444 0.641 0.693
1 5 0.123 0.202 0.610 0.383 0.585 0.655
2 5 0.133 0.216 0.617 0.451 0.616 0.732
3 5 0.133 0.245 0.544 0.398 0.603 0.659
4 5 0.142 0.227 0.625 0.413 0.578 0.714
1 6 0.136 0.224 0.609 0.353 0.526 0.670
2 6 0.152 0.220 0.690 0.389 0.545 0.714
3 6 0.127 0.215 0.591 0.384 0.573 0.670
4 6 0.153 0.221 0.692 0.392 0.497 0.789
Trt 1: negative control diet (0.45% cornstarch). 
Trt 2: diet + 0.25% carbadox + 0.20% cornstarch. 
Trt 3: diet + 0.20% beta-glucan + 0.25% cornstarch.   
Trt 4: diet + 0.20% beta-glucan + 0.25% carbadox. 
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Appendix Table 8. Analysis of variance for average daily gain, average daily feed intake, 
and gain:feed for Nursery Phase 1 and Phase 2 - Experiment 2. 
 Mean Squares 
Phase 1  Phase 2 
Source d.f. ADG ADFI G:F  ADG ADFI G:F 
Total 23        
Error 15 0.00027 0.00040 0.00188 0.00066 0.00072 0.00119
Repetition 5 0.00089 0.00020 0.01203 0.01589 0.02914 0.00113
Treatment 3 0.00066 0.00035 0.00475 0.00260 0.00160 0.00392
No AB vs AB 1 0.00132 0.00103 0.00383 0.00683 0.00273 0.00739
No BG vs BG 1 0.00049 0.00001 0.00690 0.00061 1.50E-06 0.00363
AB x BG 1 0.00016 0.00001 0.00353 0.00036 0.00205 0.00074
Coefficient of         
Variation, %   10.71 8.82 6.35  6.97 5.08 4.94 
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Appendix Table 9. Means for average daily gain, average daily feed intake, and 
gain:feed for Nursery Phases 1 & 2 combined and Phase 3 - Experiment 2. 
 Phases 1 & 2  Phases 3 
Trt Rep ADG (kg) ADFI (kg) G:F  ADG (kg) ADFI (kg) G:F 
1 1 0.227 0.335 0.677 0.488 0.806 0.605
2 1 0.247 0.365 0.676 0.506 0.801 0.631
3 1 0.249 0.356 0.699 0.480 0.784 0.612
4 1 0.275 0.375 0.735 0.504 0.820 0.615
1 2 0.220 0.337 0.654 0.430 0.735 0.586
2 2 0.254 0.392 0.648 0.429 0.792 0.542
3 2 0.228 0.321 0.709 0.449 0.684 0.657
4 2 0.288 0.385 0.748 0.531 0.824 0.644
1 3 0.223 0.321 0.695 0.444 0.720 0.617
2 3 0.220 0.316 0.698 0.419 0.695 0.604
3 3 0.234 0.315 0.744 0.425 0.684 0.622
4 3 0.239 0.326 0.733 0.416 0.655 0.635
1 4 0.298 0.418 0.712 0.546 0.863 0.633
2 4 0.335 0.472 0.709 0.574 0.938 0.612
3 4 0.298 0.434 0.685 0.553 0.913 0.605
4 4 0.315 0.441 0.715 0.582 0.930 0.626
1 5 0.253 0.393 0.643 0.562 0.863 0.652
2 5 0.292 0.416 0.702 0.536 0.865 0.620
3 5 0.266 0.424 0.626 0.562 0.954 0.589
4 5 0.277 0.402 0.690 0.574 0.966 0.594
1 6 0.245 0.375 0.653 0.537 0.828 0.649
2 6 0.271 0.383 0.707 0.533 0.863 0.618
3 6 0.256 0.395 0.648 0.550 0.892 0.617
4 6 0.272 0.359 0.759 0.563 0.881 0.639
Trt 1: negative control diet (0.45% cornstarch). 
Trt 2: diet + 0.25% carbadox + 0.20% cornstarch. 
Trt 3: diet + 0.20% beta-glucan + 0.25% cornstarch.   
Trt 4: diet + 0.20% beta-glucan + 0.25% carbadox. 
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Appendix Table 10. Analysis of variance for average daily gain, average daily feed 
intake, and gain:feed for Nursery Phases 1 & 2 combined and Phase 3 - Experiment 2. 
 Mean Squares 
Phases 1 & 2  Phase 3 
Source d.f. ADG ADFI G:F  ADG ADFI G:F 
Total 23        
Error 15 0.00017 0.00033 0.00083 0.00046 0.00157 0.00077
Repetition 5 0.00321 0.00732 0.00123 0.01305 0.03211 0.00024
Treatment 3 0.00133 0.00081 0.00372 0.00111 0.00195 0.00054
No AB vs AB 1 0.00346 0.00180 0.00586 0.00083 0.00385 0.00017
No BG vs BG 1 0.00052 4.17E-06 0.00419 0.00143 0.00198 0.00031
AB x BG 1 0.00001 0.00062 0.00111 0.00108 0.00003 0.00115
Coefficient of         
Variation, %   4.92 4.85 4.15  4.20 4.81 4.48 
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Appendix Table 11. Means for average daily gain, average daily feed intake, 
and gain:feed for the entire 42-d nursery period - Experiment 2. 
 Overall 
Trt  Rep ADG ADFI GF 
1 1 0.313 0.492 0.637 
2 1 0.333 0.511 0.652 
3 1 0.326 0.498 0.654 
4 1 0.351 0.523 0.672 
1 2 0.290 0.469 0.618 
2 2 0.312 0.525 0.595 
3 2 0.302 0.443 0.682 
4 2 0.369 0.532 0.694 
1 3 0.297 0.454 0.654 
2 3 0.286 0.442 0.649 
3 3 0.298 0.438 0.680 
4 3 0.298 0.436 0.684 
1 4 0.380 0.567 0.671 
2 4 0.415 0.627 0.661 
3 4 0.383 0.594 0.644 
4 4 0.404 0.604 0.669 
1 5 0.356 0.550 0.647 
2 5 0.373 0.566 0.660 
3 5 0.364 0.601 0.606 
4 5 0.376 0.590 0.638 
1 6 0.342 0.526 0.650 
2 6 0.358 0.543 0.660 
3 6 0.354 0.560 0.631 
4 6 0.369 0.533 0.693 
Trt 1: negative control diet (0.45% cornstarch). 
Trt 2: diet + 0.25% carbadox + 0.20% cornstarch. 
Trt 3: diet + 0.20% beta-glucan + 0.25% cornstarch.   
Trt 4: diet + 0.20% beta-glucan + 0.25% carbadox. 
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Appendix Table 12. Analysis of variance for average daily gain, average daily feed  
intake, and gain:feed for the entire 42-d period - Experiment 2. 
 Mean Squares 
Overall 
Source d.f. ADG ADFI G:F 
Total 23    
Error 15 0.00018 0.00051 0.00061 
Repetition 5 0.00528 0.01318 0.00044 
Treatment 3 0.00109 0.00096 0.00117 
 No AB vs AB 1 0.00238 0.00240 0.00098 
 No BG vs BG 1 0.00081 0.00027 0.00155 
 AB x BG 1 0.00007 0.00022 0.00098 
Coefficient of     
Variation, %   3.94 4.28 3.77 
109
Appendix Table 13. Means for average daily gain, average daily feed intake, and  
gain:feed for Finisher Phase 1 and Phase 2 - Experiment 2. 
 Phase 1  Phase 2 
Trt Rep ADG (kg) ADFI (kg) G:F  ADG (kg) ADFI (kg) G:F 
1 1 0.704 1.458 0.483 0.686 1.818 0.378
2 1 0.735 1.614 0.456 0.697 1.996 0.349
3 1 0.701 1.532 0.457 0.742 2.118 0.35 
4 1 0.765 1.669 0.459 0.859 2.426 0.354
1 2 0.641 1.358 0.471 0.645 1.944 0.331
2 2 0.671 1.586 0.423 0.851 2.302 0.37 
3 2 0.735 1.592 0.462 0.754 2.265 0.333
4 2 0.719 1.583 0.454 0.693 2.068 0.335
1 3 0.693 1.501 0.462 0.706 2.082 0.339
2 3 0.605 1.404 0.431 0.742 2.026 0.366
3 3 0.712 1.418 0.502 0.746 2.211 0.337
4 3 0.639 1.508 0.424 0.865 2.724 0.318
1 4 0.717 1.674 0.429 0.835 2.249 0.371
2 4 0.854 1.971 0.433 0.864 2.598 0.332
3 4 0.745 1.554 0.479 0.649 1.799 0.361
4 4 0.731 1.564 0.468 0.864 2.592 0.333
1 5 0.757 1.687 0.449 0.832 2.348 0.355
2 5 0.721 1.580 0.456 0.854 2.288 0.373
3 5 0.701 1.379 0.508 1.088 2.508 0.434
4 5 0.822 1.788 0.46 0.903 2.265 0.399
1 6 0.831 1.759 0.472 0.746 2.245 0.332
2 6 0.770 1.624 0.475 0.831 2.381 0.349
3 6 0.764 1.599 0.478 0.838 2.370 0.353
4 6 0.666 1.397 0.477 0.754 2.008 0.376
Trt 1: negative control diet (0.30% cornstarch). 
Trt 2: diet + 0.10% chlortetracycline + 0.20% cornstarch. 
Trt 3: diet + 0.20% beta-glucan + 0.10% cornstarch.   
Trt 4: diet + 0.20% beta-glucan + 0.10% chlortetracycline. 
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Appendix Table 14. Analysis of variance for average daily gain, average daily feed 
intake, and gain:feed for Finisher Phase 1 and Phase 2 - Experiment 2. 
 Mean Squares 
Phase 1  Phase 2 
Source d.f. ADG ADFI G:F  ADG ADFI G:F 
Total 23        
Error 15 0.00331 0.02028 0.00038 0.00760 0.06453 0.00054
Repetition 5 0.00650 0.02460 0.00037 0.01786 0.03962 0.00134
Treatment 3 0.00001 0.01407 0.00130 0.00763 0.05718 0.00013
No AB vs AB 1 3.70E-07 0.02516 0.00232 0.01084 0.12284 0.00002
No BG vs BG 1 4.00E-08 0.01670 0.00147 0.00905 0.04833 0.00006
AB x BG 1 0.00004 0.00036 0.00011 0.00299 0.00036 0.00031
Coefficient of         
Variation, %   7.94 9.04 4.25  10.98 11.37 6.53 
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Appendix Table 15. Means for average daily gain, average daily feed intake, and 
gain:feed for Finisher Phase 3 and the entire grow-finish stage - Experiment 2. 
 Phase 3  Overall 
Trt Rep ADG (kg) ADFI (kg) G:F  ADG (kg) ADFI (kg) G:F 
1 1 0.632 2.403 0.263 0.666 1.979 0.337
2 1 0.667 2.274 0.294 0.695 2.010 0.346
3 1 0.740 2.624 0.282 0.729 2.177 0.335
4 1 0.835 2.813 0.297 0.729 2.377 0.345
1 2 0.742 2.377 0.312 0.682 1.909 0.358
2 2 0.836 2.860 0.292 0.781 2.270 0.344
3 2 0.754 2.640 0.286 0.747 2.176 0.344
4 2 0.785 2.725 0.288 0.740 2.159 0.343
1 3 0.757 2.612 0.29 0.722 2.087 0.346
2 3 0.646 2.324 0.278 0.654 1.923 0.340
3 3 0.701 2.801 0.25 0.716 2.162 0.331
4 3 0.723 2.884 0.251 0.717 2.260 0.317
1 4 0.696 2.633 0.264 0.740 2.262 0.327
2 4 0.915 2.935 0.312 0.884 2.576 0.343
3 4 0.966 2.840 0.34 0.816 2.190 0.372
4 4 0.773 2.562 0.302 0.787 2.295 0.343
1 5 0.808 2.635 0.307 0.796 2.249 0.354
2 5 0.818 2.611 0.313 0.792 2.189 0.362
3 5 0.956 2.874 0.333 0.894 2.276 0.393
4 5 0.838 2.593 0.323 0.846 2.248 0.376
1 6 0.873 2.633 0.332 0.824 2.229 0.370
2 6 0.934 2.840 0.329 0.849 2.294 0.370
3 6 0.977 2.998 0.326 0.864 2.335 0.370
4 6 0.926 2.529 0.366 0.789 1.995 0.395
Trt 1: negative control diet (0.30% cornstarch). 
Trt 2: diet + 0.10% chlortetracycline + 0.20% cornstarch. 
Trt 3: diet + 0.20% beta-glucan + 0.10% cornstarch.   
Trt 4: diet + 0.20% beta-glucan + 0.10% chlortetracycline. 
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Appendix Table 16. Analysis of variance for average daily gain, average daily feed 
intake, and gain:feed for Finisher Phase 3 and the entire grow-finish stage - Experiment 2. 
 Mean Squares 
Phase 3  Overall 
Source d.f. ADG ADFI G:F  ADG ADFI G:F 
Total 23        
Error 15 0.00486 0.03770 0.00043 0.00148 0.02318 0.00019
Repetition 5 0.02908 0.02585 0.00256 0.01510 0.02904 0.00119
Treatment 3 0.00978 0.06328 0.00012 0.00326 0.01461 0.00009
No AB vs AB 1 0.00037 0.00060 0.00015 0.00019 0.01330 0.00001
No BG vs BG 1 0.01760 0.12702 0.00014 0.00348 0.01887 0.00019
AB x BG 1 0.01135 0.06222 0.00007 0.00611 0.01166 0.00006
Coefficient of         
Variation, %   8.67 7.28 6.85  5.01 6.94 3.92 
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Appendix Table 17. Means for average daily gain, average daily feed intake, 
and gain:feed from nursery to finisher stage - Experiment 2. 
 Nursery-Finisher 
Trt  Rep ADG (kg) ADFI (kg) G:F 
1 1 0.609 1.554 0.392
2 1 0.643 1.561 0.412
3 1 0.659 1.684 0.392
4 1 0.738 1.839 0.401
1 2 0.614 1.486 0.413
2 2 0.703 1.749 0.402
3 2 0.666 1.672 0.398
4 2 0.682 1.679 0.406
1 3 0.639 1.607 0.398
2 3 0.591 1.491 0.397
3 3 0.653 1.660 0.393
4 3 0.695 1.742 0.399
1 4 0.654 1.687 0.388
2 4 0.775 1.934 0.401
3 4 0.774 1.789 0.432
4 4 0.699 1.737 0.402
1 5 0.690 1.675 0.412
2 5 0.693 1.642 0.422
3 5 0.773 1.710 0.452
4 5 0.747 1.695 0.441
1 6 0.706 1.644 0.430
2 6 0.729 1.710 0.426
3 6 0.738 1.745 0.423
4 6 0.667 1.494 0.446
Trt 1: negative control diet. 
Trt 2: diet + antibiotic. 
Trt 3: diet + beta-glucan. 
Trt 4: diet + beta-glucan + antibiotic. 
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Appendix Table 18. Analysis of variance for average daily gain, average daily feed 
intake, and gain:feed from nursery to finisher stage - Experiment 2. 
 Mean Squares 
Nursery-Finisher 
Source d.f. ADG ADFI G:F 
Total 23    
Error 15 0.00167 0.01077 0.00016 
Repetition 5 0.00507 0.01343 0.00100 
Treatment 3 0.00415 0.01231 0.00014 
 No AB vs AB 1 0.00146 0.00540 0.00004 
 No BG vs BG 1 0.00825 0.02077 0.00035 
 AB x BG 1 0.00275 0.01075 0.00002 
Coefficient of     
Variation, %   5.92 6.20 3.03 
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Appendix Table 19. Means for hot carcass weight, 10th rib backfat,  
longissimus muscle area, and fat-free lean carcass of pigs - Experiment 2. 
 Carcass 
Trt  Rep HCW 10th rib LMA FFLC 
1 1 180.00 1.91 44.58 53.88
2 1 192.50 2.29 45.42 51.86
3 1 195.00 2.29 48.52 52.44
4 1 207.50 2.41 48.00 51.38
1 2 179.00 2.67 42.52 49.81
2 2 205.00 3.30 42.39 46.56
3 2 191.50 2.54 44.71 50.43
4 2 175.00 2.03 42.97 52.99
1 3 181.00 1.91 41.94 52.95
2 3 177.00 1.40 48.71 57.42
3 3 178.50 2.16 43.35 52.08
4 3 188.50 2.54 48.58 51.44
1 4 196.00 1.91 49.81 54.34
2 4 203.50 2.41 44.52 50.66
3 4 176.50 2.16 45.81 52.97
4 4 200.00 2.16 42.71 51.46
1 5 186.50 2.29 43.23 51.42
2 5 184.00 1.78 42.71 53.64
3 5 192.50 2.29 39.68 50.33
4 5 195.50 2.03 42.00 51.96
1 6 171.50 2.29 36.97 50.09
2 6 195.50 3.05 39.61 46.94
3 6 191.50 3.94 39.68 43.14
4 6 172.50 1.91 40.84 52.99
Trt 1: negative control diet. 
Trt 2: diet + antibiotic. 
Trt 3: diet + beta-glucan. 
Trt 4: diet + beta-glucan + antibiotic. 
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Appendix Table 20. Analysis of variance for 10th rib backfat, longissimus muscle  
area, and fat-free lean carcass of pigs - Experiment 2. 
 Mean Squares 
Carcass 
Source d.f. 10th Rib LMA FFLC 
Total 23    
Error 14 0.12019 6.47772 3.05062 
Repetition 5 0.60646 29.25478 20.52457 
Treatment 3 0.23956 0.79721 5.91244 
 No AB vs AB 1 0.51389 1.67620 14.21726 
 No BG vs BG 1 0.02598 0.76544 0.51705 
 AB x BG 1 0.12498 0.00637 1.86262 
HCW 1 2.04557 0.20374 57.40974 
Coefficient of     
Variation, %   14.95 5.82 3.40 
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Appendix Table 21. Means for average daily gain, average daily feed intake, and 
gain:feed for Phase 1 and Phase 2 – Experiment 3. 
Phase 1  Phase 2 
Trt Rep ADG (kg) ADFI (kg) G:F  ADG (kg) ADFI (kg) G:F 
1 1 0.194 0.288 0.674  0.349 0.621 0.562 
2 1 0.195 0.260 0.750  0.403 0.638 0.632 
3 1 0.168 0.226 0.742  0.344 0.512 0.672 
4 1 0.152 0.214 0.711  0.372 0.579 0.642 
5 1 0.209 0.276 0.757  0.417 0.644 0.647 
1 2 0.183 0.216 0.849  0.346 0.531 0.653 
2 2 0.182 0.237 0.765  0.426 0.609 0.700 
3 2 0.207 0.249 0.832  0.374 0.544 0.687 
4 2 0.196 0.257 0.763  0.345 0.498 0.694 
5 2 0.194 0.228 0.849  0.353 0.537 0.658 
1 3 0.157 0.220 0.711  0.306 0.539 0.568 
2 3 0.149 0.188 0.797  0.404 0.579 0.697 
3 3 0.207 0.233 0.887  0.253 0.471 0.537 
4 3 0.146 0.192 0.759  0.306 0.477 0.642 
5 3 0.112 0.169 0.662  0.304 0.440 0.690 
1 4 0.193 0.245 0.790  0.313 0.538 0.582 
2 4 0.168 0.261 0.643  0.324 0.583 0.556 
3 4 0.188 0.255 0.738  0.350 0.550 0.636 
4 4 0.097 0.167 0.579  0.311 0.514 0.605 
5 4 0.191 0.258 0.741  0.358 0.559 0.640 
1 5 0.133 0.168 0.791  0.274 0.490 0.558 
2 5 0.135 0.163 0.830  0.303 0.471 0.644 
3 5 0.126 0.167 0.753  0.281 0.432 0.650 
4 5 0.122 0.153 0.795  0.264 0.464 0.569 
5 5 0.090 0.120 0.751  0.340 0.388 0.876 
1 6 0.147 0.173 0.850  0.299 0.469 0.638 
2 6 0.153 0.184 0.832  0.277 0.436 0.635 
3 6 0.192 0.202 0.955  0.278 0.446 0.623 
4 6 0.178 0.197 0.901  0.320 0.527 0.606 
5 6 0.156 0.195 0.802  0.346 0.508 0.680 
1 7 0.187 0.252 0.739  0.371 0.638 0.581 
2 7 0.135 0.192 0.702  0.333 0.575 0.579 
3 7 0.158 0.220 0.721  0.442 0.616 0.718 
4 7 0.140 0.188 0.748  0.336 0.582 0.577 
5 7 0.171 0.233 0.733  0.298 0.584 0.511 
1 8 0.165 0.239 0.689  0.298 0.581 0.514 
2 8 0.150 0.215 0.700  0.350 0.563 0.622 
3 8 0.133 0.194 0.689  0.323 0.499 0.647 
4 8 0.147 0.211 0.696  0.306 0.490 0.624 
5 8 0.230 0.310 0.741  0.304 0.574 0.529 
Trt 1: basal diet (BD). 
Trt 2: BD + 0.25% carbadox. 
Trt 3: BD + 0.20% beta-glucan. 
Trt 4: BD + 0.20% acidifier. 
Trt 5: BD + 0.20% beta-glucan + 0.20% acidifier. 
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Appendix Table 22. Analysis of variance for average daily gain, average daily feed 
intake, and gain:feed for Phase 1 and Phase 2 - Experiment 3. 
 Mean Squares 
Phase 1  Phase 2 
Source d.f. ADG ADFI G:F  ADG ADFI G:F 
Total 39        
Error 28 0.00074 0.00084 0.00298 0.00133 0.00153 0.00412
Repetition 7 0.00226 0.00522 0.01719 0.00490 0.01450 0.00504
Treatment 4 0.00088 0.00101 0.00245 0.00157 0.00352 0.00641
Coefficient of         
Variation, %   16.65 13.43 7.18  10.97 7.34 10.24 
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Appendix Table 23. Means for average daily gain, average daily feed intake, and gain:feed 
for Phases 1 & 2 combined and Phase 3 – Experiment 3. 
Phase 1 & 2  Phase 3 
Trt Rep ADG (kg) ADFI (kg) G:F  ADG (kg) ADFI (kg) G:F 
1 1 0.271 0.454 0.597 0.336 0.890 0.378
2 1 0.299 0.449 0.665 0.258 0.537 0.481
3 1 0.256 0.369 0.693 0.317 0.636 0.499
4 1 0.253 0.382 0.663 0.297 0.568 0.524
5 1 0.313 0.460 0.680 0.279 0.756 0.369
1 2 0.265 0.373 0.710 0.223 0.464 0.481
2 2 0.304 0.423 0.718 0.319 0.566 0.563
3 2 0.291 0.397 0.733 0.311 0.600 0.519
4 2 0.271 0.377 0.717 0.256 0.463 0.553
5 2 0.273 0.383 0.714 0.274 0.567 0.484
1 3 0.232 0.380 0.610 0.264 0.568 0.464
2 3 0.277 0.384 0.722 0.252 0.505 0.499
3 3 0.230 0.352 0.652 0.334 0.597 0.560
4 3 0.226 0.334 0.677 0.308 0.587 0.526
5 3 0.203 0.298 0.683 0.319 0.572 0.557
1 4 0.253 0.392 0.647 0.191 0.424 0.451
2 4 0.246 0.422 0.583 0.266 0.492 0.541
3 4 0.269 0.402 0.669 0.271 0.618 0.439
4 4 0.199 0.332 0.598 0.281 0.755 0.373
5 4 0.275 0.408 0.673 0.128 0.347 0.368
1 5 0.203 0.329 0.617 0.301 0.618 0.488
2 5 0.219 0.317 0.692 0.306 0.605 0.505
3 5 0.203 0.299 0.678 0.233 0.532 0.439
4 5 0.188 0.298 0.630 0.207 0.430 0.482
5 5 0.156 0.245 0.635 0.200 0.464 0.431
1 6 0.223 0.321 0.694 0.188 0.414 0.454
2 6 0.215 0.310 0.693 0.314 0.642 0.488
3 6 0.235 0.324 0.727 0.258 0.511 0.505
4 6 0.248 0.362 0.686 0.191 0.384 0.496
5 6 0.251 0.351 0.714 0.229 0.553 0.414
1 7 0.279 0.445 0.626 0.383 0.775 0.494
2 7 0.234 0.384 0.611 0.313 0.520 0.601
3 7 0.300 0.418 0.718 0.388 0.887 0.437
4 7 0.238 0.385 0.618 0.261 0.552 0.472
5 7 0.235 0.386 0.608 0.256 0.581 0.440
1 8 0.232 0.410 0.565 0.253 0.487 0.519
2 8 0.250 0.389 0.644 0.345 0.666 0.518
3 8 0.228 0.346 0.659 0.274 0.499 0.548
4 8 0.227 0.350 0.646 0.206 0.444 0.464
5 8 0.266 0.442 0.603 0.401 0.775 0.517 
Trt 1: basal diet (BD). 
Trt 2: BD + 0.25% carbadox. 
Trt 3: BD + 0.20% beta-glucan. 
Trt 4: BD + 0.20% acidifier. 
Trt 5: BD + 0.20% beta-glucan + 0.20% acidifier..
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Appendix Table 24. Analysis of variance for average daily gain, average daily feed 
intake, and gain:feed for Phases 1 & 2 combined and Phase 3 - Experiment 3. 
 Mean Squares 
Phases 1 & 2  Phase 3 
Source d.f. ADG ADFI G:F  ADG ADFI G:F 
Total 39        
Error 28 0.00056 0.00099 0.00091 0.00283 0.01542 0.00204
Repetition 7 0.00388 0.00860 0.00569 0.00560 0.02135 0.00539
Treatment 4 0.00068 0.00175 0.00350 0.00370 0.00794 0.00676
Coefficient of         
Variation, %   9.64 8.46 4.56  19.35 21.74 9.34 
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Appendix Table 25. Means for average daily gain, average daily feed intake, and  
gain:feed for the entire 42-d period - Experiment 3. 
 Overall 
Trt  Rep ADG (kg) ADFI (kg) G:F 
1 1 0.293 0.600 0.489 
2 1 0.286 0.478 0.597 
3 1 0.276 0.458 0.603 
4 1 0.267 0.441 0.607 
5 1 0.302 0.559 0.540 
1 2 0.251 0.404 0.622 
2 2 0.309 0.471 0.656 
3 2 0.298 0.464 0.641 
4 2 0.266 0.406 0.654 
5 2 0.274 0.444 0.617 
1 3 0.242 0.443 0.547 
2 3 0.268 0.424 0.633 
3 3 0.265 0.434 0.610 
4 3 0.253 0.418 0.606 
5 3 0.241 0.387 0.622 
1 4 0.233 0.402 0.579 
2 4 0.252 0.445 0.567 
3 4 0.270 0.474 0.569 
4 4 0.226 0.469 0.482 
5 4 0.226 0.388 0.582 
1 5 0.236 0.425 0.555 
2 5 0.248 0.413 0.601 
3 5 0.213 0.377 0.566 
4 5 0.194 0.341 0.571 
5 5 0.168 0.308 0.547 
1 6 0.211 0.352 0.600 
2 6 0.248 0.421 0.589 
3 6 0.243 0.386 0.629 
4 6 0.229 0.369 0.621 
5 6 0.244 0.419 0.582 
1 7 0.313 0.555 0.564 
2 7 0.260 0.429 0.606 
3 7 0.330 0.574 0.574 
4 7 0.246 0.440 0.559 
5 7 0.242 0.451 0.536 
1 8 0.239 0.436 0.548 
2 8 0.282 0.481 0.586 
3 8 0.243 0.397 0.613 
4 8 0.220 0.382 0.576 
5 8 0.311 0.553 0.563 
Trt 1: basal diet (BD). 
Trt 2: BD + 0.25% carbadox. 
Trt 3: BD + 0.20% beta-glucan. 
Trt 4: BD + 0.20% acidifier. 
Trt 5: BD + 0.20% beta-glucan + 0.20% acidifier. 
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Appendix Table 26. Analysis of variance for average daily gain, average daily feed  
intake, and gain:feed for the entire 42-d period - Experiment 3. 
 Mean Squares 
Overall 
Source d.f. ADG ADFI G:F 
Total 39    
Error 28 0.00060 0.00260 0.00078 
Repetition 7 0.00321 0.01037 0.00381 
Treatment 4 0.00135 0.00239 0.00247 
Coefficient of     
Variation, %   9.58 11.64 4.77 
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Appendix Table 27. Means for average daily gain, average daily feed intake, and 
gain:feed for Phase 1 and Phase 2 - Experiment 4. 
 Phase 1  Phase 2 
Trt Rep ADG (kg) ADFI (kg) G:F  ADG (kg) ADFI (kg) G:F 
1 1 0.184 0.311 0.592 0.386 0.635 0.608
2 1 0.209 0.310 0.673 0.390 0.671 0.581
3 1 0.182 0.285 0.638 0.427 0.684 0.624
4 1 0.240 0.319 0.752 0.419 0.648 0.648
5 1 0.182 0.300 0.605 0.373 0.616 0.605
1 2 0.173 0.287 0.602 0.350 0.612 0.571
2 2 0.157 0.280 0.562 0.480 0.785 0.611
3 2 0.192 0.299 0.643 0.396 0.637 0.622
4 2 0.169 0.304 0.558 0.401 0.663 0.605
5 2 0.200 0.331 0.604 0.433 0.676 0.640
1 3 0.167 0.252 0.662 0.377 0.634 0.595
2 3 0.159 0.308 0.515 0.381 0.607 0.629
3 3 0.188 0.284 0.660 0.420 0.628 0.669
4 3 0.189 0.346 0.547 0.383 0.669 0.573
5 3 0.187 0.304 0.613 0.372 0.619 0.602
1 4 0.128 0.222 0.575 0.441 0.712 0.619
2 4 0.178 0.277 0.641 0.370 0.551 0.671
3 4 0.150 0.245 0.611 0.360 0.572 0.629
4 4 0.152 0.237 0.639 0.410 0.644 0.636
5 4 0.178 0.235 0.760 0.326 0.452 0.722
Trt 1: basal diet (BD). 
Trt 2: BD + 0.25% carbadox. 
Trt 3: BD + 0.20% beta-glucan. 
Trt 4: BD + probiotic. 
Trt 5: BD + 0.20% beta-glucan + probiotic. 
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Appendix Table 28. Analysis of variance for average daily gain, average daily feed 
intake, and gain:feed for Phase 1 and Phase 2 - Experiment 4. 
 Mean Squares 
Phase 1  Phase 2 
Source d.f. ADG ADFI G:F  ADG ADFI G:F 
Total 19        
Error 12 0.00040 0.00048 0.00433 0.00154 0.00414 0.00106
Repetition 3 0.00148 0.00426 0.00457 0.00093 0.00702 0.00235
Treatment 4 0.00040 0.00072 0.00160 0.00061 0.00294 0.00121
Coefficient of         
Variation, %   11.23 7.67 10.56  9.93 10.12 5.23 
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Appendix Table 29. Means for average daily gain, average daily feed intake, and 
gain:feed for Phases 1 & 2 combined and Phase 3 - Experiment 4. 
 Phases 1 & 2  Phase 3 
Trt Rep ADG (kg) ADFI (kg) G:F  ADG (kg) ADFI (kg) G:F 
1 1 0.285 0.473 0.603 0.318 0.673 0.472
2 1 0.300 0.491 0.611 0.363 0.621 0.584
3 1 0.305 0.484 0.629 0.326 0.796 0.410
4 1 0.330 0.484 0.682 0.367 0.715 0.514
5 1 0.277 0.458 0.606 0.378 0.566 0.669
1 2 0.262 0.450 0.581 0.333 0.855 0.390
2 2 0.309 0.518 0.597 0.362 0.758 0.478
3 2 0.295 0.468 0.629 0.368 0.882 0.417
4 2 0.285 0.483 0.590 0.315 0.796 0.395
5 2 0.317 0.504 0.629 0.317 0.697 0.455
1 3 0.272 0.443 0.614 0.282 0.714 0.395
2 3 0.270 0.457 0.591 0.309 0.732 0.422
3 3 0.304 0.456 0.666 0.268 0.630 0.426
4 3 0.286 0.508 0.564 0.263 0.644 0.409
5 3 0.280 0.461 0.606 0.318 0.672 0.473
1 4 0.267 0.439 0.607 0.205 0.717 0.286
2 4 0.274 0.414 0.661 0.248 0.523 0.474
3 4 0.255 0.409 0.623 0.222 0.510 0.436
4 4 0.274 0.430 0.637 0.224 0.548 0.408
5 4 0.252 0.343 0.735 0.227 0.466 0.488
Trt 1: basal diet (BD). 
Trt 2: BD + 0.25% carbadox. 
Trt 3: BD + 0.20% beta-glucan. 
Trt 4: BD + probiotic. 
Trt 5: BD + 0.20% beta-glucan + probiotic. 
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Appendix Table 30. Analysis of variance for average daily gain, average daily feed 
intake, and gain:feed for Phases 1 & 2 combined and Phase 3 - Experiment 4. 
 Mean Squares 
Phases 1 & 2  Phase 3 
Source d.f. ADG ADFI G:F  ADG ADFI G:F 
Total 19        
Error 12 0.00029 0.00072 0.00144 0.00044 0.00453 0.00233
Repetition 3 0.00119 0.00626 0.00237 0.01633 0.04996 0.01420
Treatment 4 0.00030 0.00081 0.00119 0.00083 0.01092 0.01188
Coefficient of         
Variation, %   5.99 5.84 6.08  7.00 9.96 10.73 
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Appendix Table 31. Means for average daily gain, average daily feed intake, 
and gain:feed for the entire 42-d period - Experiment 4. 
 Overall 
Trt  Rep ADG (kg) ADFI (kg) G:F 
1 1 0.296 0.540 0.548
2 1 0.321 0.534 0.600
3 1 0.312 0.588 0.530
4 1 0.342 0.561 0.611
5 1 0.311 0.494 0.630
1 2 0.286 0.585 0.488
2 2 0.326 0.595 0.548
3 2 0.319 0.606 0.527
4 2 0.295 0.587 0.502
5 2 0.317 0.568 0.558
1 3 0.276 0.533 0.517
2 3 0.283 0.549 0.515
3 3 0.292 0.514 0.568
4 3 0.279 0.553 0.504
5 3 0.292 0.532 0.550
1 4 0.248 0.525 0.472
2 4 0.265 0.450 0.589
3 4 0.244 0.443 0.552
4 4 0.259 0.465 0.557
5 4 0.244 0.385 0.635
Trt 1: basal diet (BD). 
Trt 2: BD + 0.25% carbadox. 
Trt 3: BD + 0.20% beta-glucan. 
Trt 4: BD + probiotic. 
Trt 5: BD + 0.20% beta-glucan + probiotic. 
 
128
Appendix Table 32. Analysis of variance for average daily gain, average daily feed  
intake, and gain:feed for the entire 42-d period - Experiment 4. 
 Mean Squares 
Overall 
Source d.f. ADG ADFI G:F 
Total 19    
Error 12 0.00015 0.00083 0.00099 
Repetition 3 0.00420 0.01574 0.00380 
Treatment 4 0.00028 0.00169 0.00403 
Coefficient of     
Variation, %   4.21 5.42 5.73 
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Appendix Table 33. Means for the IgA serum protein - Experiment 4. 
Trt Rep Day 0 Day 28 Day 42 
1 1 8.91 34.49 59.23
2 1 7.78 27.41 77.68
3 1 6.55 44.28 47.54
4 1 11.92 33.86 51.02
5 1 7.03 45.15 74.89
1 2 12.31 31.10 34.35
2 2 10.15 . .
3 2 10.02 24.04 27.06
4 2 6.25 18.20 27.37
5 2 9.05 24.97 36.00
1 3 7.82 47.74 70.86
2 3 6.88 31.30 39.24
3 3 6.11 22.57 34.43
4 3 10.26 35.35 84.65
5 3 14.38 55.16 59.75
1 4 11.31 29.99 43.10
2 4 7.13 36.18 82.41
3 4 8.90 34.32 73.98
4 4 . 44.21 61.16
5 4 9.30 50.57 55.01
Trt 1: basal diet (BD). 
Trt 2: BD + 0.25% carbadox. 
Trt 3: BD + 0.20% beta-glucan. 
Trt 4: BD + probiotic. 
Trt 5: BD + 0.20% beta-glucan + probiotic. 
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Appendix Table 34. Analysis of variance for IgA serum protein - Experiment 4. 
Mean Squares 
 day of collection 
Source d.f. 0 28 42
Total 18    
Error 11 4.20854 71.49875 358.81996 
Repetition 3 8.61112 274.20250 310.81690 
Treatment 4 5.41946 60.56370 373.51230 
Coefficient of     
Variation, %   22.65 23.95 34.62 
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Appendix Table 35. Means for the IgG serum protein - Experiment 4. 
Trt Rep Day 0 Day 28 Day 42 
1 1 521.03 447.00 654.97 
2 1 549.60 372.80 491.22 
3 1 254.06 328.17 395.57 
4 1 437.72 236.72 399.22 
5 1 594.30 359.03 590.63 
1 2 653.30 354.63 424.93 
2 2 . . .
3 2 621.77 275.20 374.43 
4 2 355.63 251.03 348.73 
5 2 386.37 273.27 374.40 
1 3 491.30 350.67 441.27 
2 3 434.12 257.65 251.33 
3 3 534.87 278.63 440.43 
4 3 625.87 323.10 574.50 
5 3 416.83 751.48 589.17 
1 4 . 575.75 572.20 
2 4 458.50 378.50 534.00 
3 4 554.63 299.67 405.97 
4 4 897.28 330.00 477.30 
5 4 . 547.38 438.50 
Trt 1: basal diet (BD). 
Trt 2: BD + 0.25% carbadox. 
Trt 3: BD + 0.20% beta-glucan. 
Trt 4: BD + probiotic. 
Trt 5: BD + 0.20% beta-glucan + probiotic. 
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Appendix Table 36. Analysis of variance for IgG serum protein - Experiment 4. 
Mean Squares 
 day of collection 
Source d.f. 0 14 28
Total 18    
Error 11 20412.46050 17147.86020 7496.23970 
Repetition 3 3355.95950 10005.10717 9865.61724 
Treatment 4 34938.57410 21300.71696 18981.95134 
Coefficient of     
Variation, %   27.64 35.59 18.74 
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Appendix Table 37. Means of average daily gain, average daily feed intake, and 
gain:feed for Phase 1 and Phase 2 from Experiment 1 to Experiment 4 (26 reps).  
Phase 1  Phase 2 
Exp Trt Rep ADG (kg) ADFI (kg) G:F  ADG (kg) ADFI (kg) G:F 
1 NC 1 0.144 0.262 0.550 0.355 0.548 0.649
1 AB 1 0.155 0.304 0.510 0.431 0.612 0.704
1 BG 1 0.194 0.300 0.646 0.445 0.681 0.654
1 NC 2 0.150 0.228 0.658 0.370 0.531 0.696
1 AB 2 0.118 0.183 0.641 0.342 0.498 0.687
1 BG 2 0.141 0.219 0.644 0.330 0.469 0.702
1 NC 3 0.166 0.291 0.572 0.257 0.411 0.625
1 AB 3 0.130 0.320 0.408 0.296 0.455 0.651
1 BG 3 0.116 0.292 0.398 0.303 0.450 0.673
1 NC 4 0.135 0.307 0.439 0.236 0.383 0.617
1 AB 4 0.168 0.240 0.698 0.328 0.492 0.667
1 BG 4 0.106 0.239 0.442 0.260 0.395 0.659
1 NC 5 0.207 0.302 0.687 0.408 0.565 0.723
1 AB 5 0.256 0.323 0.793 0.537 0.687 0.781
1 BG 5 0.296 0.370 0.800 0.504 0.666 0.757
1 NC 6 0.215 0.264 0.813 0.443 0.625 0.709
1 AB 6 0.213 0.286 0.743 0.400 0.602 0.664
1 BG 6 0.209 0.294 0.710 0.434 0.611 0.710
1 NC 7 0.179 0.253 0.707 0.415 0.542 0.766
1 AB 7 0.217 0.306 0.709 0.415 0.579 0.716
1 BG 7 0.183 0.271 0.674 0.379 0.612 0.619
1 NC 8 0.182 0.291 0.625 0.392 0.556 0.705
1 AB 8 0.162 0.226 0.715 0.387 0.522 0.741
1 BG 8 0.159 0.238 0.668 0.346 0.517 0.670
2 NC 1 0.157 0.222 0.707 0.296 0.448 0.661
2 AB 1 0.148 0.216 0.686 0.346 0.515 0.671
2 BG 1 0.201 0.254 0.791 0.297 0.459 0.649
2 NC 2 0.153 0.227 0.673 0.287 0.447 0.643
2 AB 2 0.178 0.272 0.655 0.330 0.512 0.644
2 BG 2 0.132 0.191 0.689 0.324 0.452 0.718
2 NC 3 0.163 0.227 0.719 0.283 0.415 0.683
2 AB 3 0.168 0.230 0.729 0.272 0.401 0.680
2 BG 3 0.154 0.200 0.771 0.314 0.429 0.730
2 NC 4 0.138 0.207 0.670 0.457 0.630 0.726
2 AB 4 0.149 0.242 0.617 0.520 0.701 0.741
2 BG 4 0.146 0.221 0.660 0.449 0.649 0.693
2 NC 5 0.123 0.202 0.610 0.383 0.585 0.655
2 AB 5 0.133 0.216 0.617 0.451 0.616 0.732
2 BG 5 0.133 0.245 0.544 0.398 0.603 0.659
NC: negative control diet (BD). 
AB: BD + 0.25% carbadox. 
BG: BD + 0.20% beta-glucan. 
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Appendix Table 38. Means of average daily gain, average daily feed intake, and 
gain:feed for Phase 1 and Phase 2 from Experiment 1 to Experiment 4 (26 reps). 
Phase 1  Phase 2 
Exp Trt Rep ADG (kg) ADFI (kg) G:F  ADG (kg) ADFI (kg) G:F 
2 NC 6 0.136 0.224 0.609 0.353 0.526 0.670
2 AB 6 0.152 0.220 0.690 0.389 0.545 0.714
2 BG 6 0.127 0.215 0.591 0.384 0.573 0.670
3 NC 1 0.194 0.288 0.674 0.349 0.621 0.562
3 AB 1 0.195 0.260 0.750 0.403 0.638 0.632
3 BG 1 0.168 0.226 0.742 0.344 0.512 0.672
3 NC 2 0.183 0.216 0.849 0.346 0.531 0.653
3 AB 2 0.182 0.237 0.765 0.426 0.609 0.700
3 BG 2 0.207 0.249 0.832 0.374 0.544 0.687
3 NC 3 0.157 0.220 0.711 0.306 0.539 0.568
3 AB 3 0.149 0.188 0.797 0.404 0.579 0.697
3 BG 3 0.207 0.233 0.887 0.253 0.471 0.537
3 NC 4 0.193 0.245 0.790 0.313 0.538 0.582
3 AB 4 0.168 0.261 0.643 0.324 0.583 0.556
3 BG 4 0.188 0.255 0.738 0.350 0.550 0.636
3 NC 5 0.133 0.168 0.791 0.274 0.490 0.558
3 AB 5 0.135 0.163 0.830 0.303 0.471 0.644
3 BG 5 0.126 0.167 0.753 0.281 0.432 0.650
3 NC 6 0.147 0.173 0.850 0.299 0.469 0.638
3 AB 6 0.153 0.184 0.832 0.277 0.436 0.635
3 BG 6 0.192 0.202 0.955 0.278 0.446 0.623
3 NC 7 0.187 0.252 0.739 0.371 0.638 0.581
3 AB 7 0.135 0.192 0.702 0.333 0.575 0.579
3 BG 7 0.158 0.220 0.721 0.442 0.616 0.718
3 NC 8 0.165 0.239 0.689 0.298 0.581 0.514
3 AB 8 0.150 0.215 0.700 0.350 0.563 0.622
3 BG 8 0.133 0.194 0.689 0.323 0.499 0.647
4 NC 1 0.184 0.311 0.592 0.386 0.635 0.608
4 AB 1 0.209 0.310 0.673 0.390 0.671 0.581
4 BG 1 0.182 0.285 0.638 0.427 0.684 0.624
4 NC 2 0.173 0.287 0.602 0.350 0.612 0.571
4 AB 2 0.157 0.280 0.562 0.480 0.785 0.611
4 BG 2 0.192 0.299 0.643 0.396 0.637 0.622
4 NC 3 0.167 0.252 0.662 0.377 0.634 0.595
4 AB 3 0.159 0.308 0.515 0.381 0.607 0.629
4 BG 3 0.188 0.284 0.660 0.420 0.628 0.669
4 NC 4 0.128 0.222 0.575 0.441 0.712 0.619
4 AB 4 0.178 0.277 0.641 0.370 0.551 0.671
4 BG 4 0.150 0.245 0.611 0.360 0.572 0.629
NC: negative control diet (BD). 
AB: BD + 0.25% carbadox. 
BG: BD + 0.20% beta-glucan. 
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Appendix Table 39. Analysis of variance for average daily gain, average daily feed 
intake, and gain:feed for Phase 1 and Phase 2 - Experiment 1 to Experiment 4 (26 reps). 
 Mean Squares 
Phase 1  Phase 2 
Source d.f. ADG ADFI G:F  ADG ADFI G:F 
Total 77        
Error 44 0.00047 0.00061 0.00378 0.00136 0.00184 0.00155 
Experiment 3 0.00245 0.02043 0.09566 0.01283 0.03941 0.02968 
Rep(Exp.) 22 0.00233 0.00241 0.01739 0.00973 0.01566 0.00236 
Treatment 2 0.00023 0.00027 0.00169 0.00576 0.00430 0.00632 
Exp. x  Trt. 6 0.00025 0.00044 0.00184 0.00015 0.00215 0.00183 
Coefficient of         
Variation, %   13.10 9.99 9.03  10.15 7.74 5.99 
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Appendix Table 40. Means of average daily gain, average daily feed intake, and 
gain:feed for Phases 1 & 2 combined from Experiment 1 to Experiment 4 (26 reps). 
Phases 1 & 2 
Exp Trt Rep ADG (kg) ADFI (kg) G:F 
1 NC 1 0.250 0.405 0.617 
1 AB 1 0.293 0.458 0.640 
1 BG 1 0.320 0.491 0.651 
1 NC 2 0.260 0.380 0.685 
1 AB 2 0.230 0.341 0.675 
1 BG 2 0.236 0.345 0.684 
1 NC 3 0.212 0.339 0.625 
1 AB 3 0.213 0.350 0.610 
1 BG 3 0.209 0.330 0.635 
1 NC 4 0.183 0.316 0.578 
1 AB 4 0.248 0.373 0.664 
1 BG 4 0.183 0.298 0.613 
1 NC 5 0.308 0.434 0.710 
1 AB 5 0.396 0.505 0.784 
1 BG 5 0.400 0.518 0.772 
1 NC 6 0.329 0.444 0.740 
1 AB 6 0.306 0.444 0.689 
1 BG 6 0.321 0.453 0.710 
1 NC 7 0.297 0.398 0.748 
1 AB 7 0.316 0.442 0.714 
1 BG 7 0.281 0.442 0.635 
1 NC 8 0.287 0.424 0.677 
1 AB 8 0.274 0.374 0.733 
1 BG 8 0.253 0.377 0.670 
2 NC 1 0.227 0.335 0.677 
2 AB 1 0.247 0.365 0.676 
2 BG 1 0.249 0.356 0.699 
2 NC 2 0.220 0.337 0.654 
2 AB 2 0.254 0.392 0.648 
2 BG 2 0.228 0.321 0.709 
2 NC 3 0.223 0.321 0.695 
2 AB 3 0.220 0.316 0.698 
2 BG 3 0.234 0.315 0.744 
2 NC 4 0.298 0.418 0.712 
2 AB 4 0.335 0.472 0.709 
2 BG 4 0.298 0.434 0.685 
2 NC 5 0.253 0.393 0.643 
2 AB 5 0.292 0.416 0.702 
2 BG 5 0.266 0.424 0.626 
NC: negative control diet (BD). 
AB: BD + 0.25% carbadox. 
BG: BD + 0.20% beta-glucan. 
137
Appendix Table 41. Means of average daily gain, average daily feed intake, and 
gain:feed for Phase 1 & 2 combined from Experiment 1 to Experiment 4 (26 reps). 
Phases 1 & 2 
Exp Trt Rep ADG (kg) ADFI (kg) G:F 
2 NC 6 0.245 0.375 0.653 
2 AB 6 0.271 0.383 0.707 
2 BG 6 0.256 0.395 0.648 
3 NC 1 0.271 0.454 0.597 
3 AB 1 0.299 0.449 0.665 
3 BG 1 0.256 0.369 0.693 
3 NC 2 0.265 0.373 0.710 
3 AB 2 0.304 0.423 0.718 
3 BG 2 0.291 0.397 0.733 
3 NC 3 0.232 0.380 0.610 
3 AB 3 0.277 0.384 0.722 
3 BG 3 0.230 0.352 0.652 
3 NC 4 0.253 0.392 0.647 
3 AB 4 0.246 0.422 0.583 
3 BG 4 0.269 0.402 0.669 
3 NC 5 0.203 0.329 0.617 
3 AB 5 0.219 0.317 0.692 
3 BG 5 0.203 0.299 0.678 
3 NC 6 0.223 0.321 0.694 
3 AB 6 0.215 0.310 0.693 
3 BG 6 0.235 0.324 0.727 
3 NC 7 0.279 0.445 0.626 
3 AB 7 0.234 0.384 0.611 
3 BG 7 0.300 0.418 0.718 
3 NC 8 0.232 0.410 0.565 
3 AB 8 0.250 0.389 0.644 
3 BG 8 0.228 0.346 0.659 
4 NC 1 0.285 0.473 0.603 
4 AB 1 0.300 0.491 0.611 
4 BG 1 0.305 0.484 0.629 
4 NC 2 0.262 0.450 0.581 
4 AB 2 0.309 0.518 0.597 
4 BG 2 0.295 0.468 0.629 
4 NC 3 0.272 0.443 0.614 
4 AB 3 0.270 0.457 0.591 
4 BG 3 0.304 0.456 0.666 
4 NC 4 0.267 0.439 0.607 
4 AB 4 0.274 0.414 0.661 
4 BG 4 0.255 0.409 0.623 
NC: negative control diet (BD). 
AB: BD + 0.25% carbadox. 
BG: BD + 0.20% beta-glucan. 
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Appendix Table 42. Analysis of variance for average daily gain, average daily feed  
intake, and gain:feed for Phases 1 & 2 combined - Experiment 1 to Experiment 4 (26 
reps). 
 Mean Squares 
Phase 1 & 2 
Source d.f. ADG ADFI G:F 
Total 77    
Error 44 0.00045 0.00063 0.00107 
Experiment 3 0.00425 0.02075 0.01206 
Rep(Exp.) 22 0.00432 0.00662 0.00364 
Treatment 2 0.00198 0.00178 0.00452 
Exp. x  Trt. 6 0.00010 0.00068 0.00144 
Coefficient of     
Variation, %   8.01 6.31 4.91 
VITA 
 
Rodel Punzalan Cueno 
 
Candidate for the Degree of 
 
Master of Science 
 
Thesis:    EVALUATION OF BETA-GLUCAN, ANTIBIOTICS, AND 
ANTIMICROBIAL ALTERNATIVES ON GROWTH PERFORMANCE AND 
IMMUNOLOGICAL PARAMETERS IN WEANLING PIGS 
 




Personal Data:  Born in Laguna, Philippines, On April 1, 1979, the son of 
Vergilio and Arminda Cueno 
 
Education:  Graduated from U.P. Rural High School in Laguna, Philippines in 
April 1996; received Bachelor of Science in Agriculture, major in 
Animal Science from University of the Philippines Los Baños, Laguna, 
Philippines in April 2000. Completed the requirements for the Master of 
Science degree in Animal Science at Oklahoma State University in July 
2005. 
 
Experience:  Employed as a Technical Assistant by Gladius Industries, Inc.; 
Employed as a Junior Animal Nutritionist by General Agri-Foods 
International, Inc.; Been a graduate research assistant at Oklahoma State 
University 
 
Professional Memberships:  Gamma Sigma Delta Honor Society in Agriculture 
(U.P. System), member of Phi Sigma Biological Sciences Honor Society 
(Alpha Chi Chapter), Fulbright Association, and the American Society 
of Animal Science.
Name: Rodel Cueno                            Date of Degree: July, 2005 
 
Institution: Oklahoma State University               Location: Stillwater, Oklahoma 
 
Title of Study: EVALUATION OF BETA-GLUCAN, ANTIBIOTICS, AND 
ANTIMICROBIAL ALTERNATIVES ON GROWTH PERFORMANCE 
AND IMMUNOLOGICAL PARAMETERS IN WEANLING PIGS  
 
Pages in Study: 138               Candidate for the Degree of Master of Science 
Major Field: Animal Science 
 
Scope and Method of Study:  Four experiments were conducted to evaluate the effects of 
beta-glucan (provided by Dong-Ahm BT, Seoul, South Korea), a product derived 
from yeast cell wall (Saccharomyces cerevisiae), along with a standard antibiotic 
and other antimicrobial alternatives (acidifier and a probiotic culture) on growth 
performance and immunological parameters in weanling pigs.  Treatments were 
replicated with four to eight pens of five to eight pigs each.  Initial BW ranged 
from 5.0 to 5.8 kg, and pigs were weaned at 19 to 21 d of age.  In each 
experiment, pigs were fed in three dietary phases (1.6, 1.4 and 1.2% tLys) during 
the 42-d study.  Pigs and feeders were weighed weekly to determine ADG, ADFI 
and G:F ratio.  Blood samples were collected and analyzed in Exp. 1 and Exp. 4.  
Experiment 2 was continued to the growing-finishing phase for carcass traits 
measurements. 
 
Findings and Conclusions:  In Exp. 1, there were no differences (P > 0.10) in ADG, 
ADFI and G:F of pigs fed diets with either carbadox or 0.20% beta-glucan but 
inclusion of 0.40% beta-glucan reduced (P < 0.10) ADG.  Addition of either 
0.20% beta-glucan or carbadox lowered (P < 0.10) CRP level at d 14.   In Exp. 2, 
there were no interactions (P > 0.10) between beta-glucan or carbadox inclusion 
though the addition of carbadox or beta-glucan increased (P < 0.05) ADG at the 
nursery phase.  Carbadox lowered (P < 0.06) 10th rib fat and improved (P < 0.05) 
percent fat-free lean.  In Exp. 3, supplementation of acidifier did not improve (P < 
0.10) growth performance of pigs.  Pigs fed beta-glucan had similar (P > 0.10) 
growth performance to pigs fed carbadox.  However, the addition of beta-glucan 
improved (P < 0.10) growth performance as compared to inclusion of acidifier 
alone.  Experiment 4 was similar to Exp. 3 except a probiotic culture was used.  
The addition of probiotic to diets with or without beta-glucan improved (P < 0.10) 
growth performance of pigs.  Serum protein levels were variable across the 
dietary treatments. On the average across all experiments, the growth performance 
of pigs fed 0.20% beta-glucan was intermediate between carbadox and the 
negative control diet. 
 
ADVISER’S APPROVAL:     Dr. Scott D. Carter 
